<SEC-DOCUMENT>0001104659-21-004956.txt : 20210119
<SEC-HEADER>0001104659-21-004956.hdr.sgml : 20210119
<ACCEPTANCE-DATETIME>20210119064132
ACCESSION NUMBER:		0001104659-21-004956
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20210119
FILED AS OF DATE:		20210119
DATE AS OF CHANGE:		20210119

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CureVac N.V.
		CENTRAL INDEX KEY:			0001809122
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39446
		FILM NUMBER:		21533805

	BUSINESS ADDRESS:	
		STREET 1:		PAUL-EHRLICH-STRABE 15 TUBINGEN
		CITY:			BADEN-WURTTEMBERG
		STATE:			2M
		ZIP:			72076
		BUSINESS PHONE:		49 7071 9883 0

	MAIL ADDRESS:	
		STREET 1:		PAUL-EHRLICH-STRABE 15 TUBINGEN
		CITY:			BADEN-WURTTEMBERG
		STATE:			2M
		ZIP:			72076

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CureVac B.V.
		DATE OF NAME CHANGE:	20200410
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>tm213031d1_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form 6-K</B></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16<BR>
OF THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the month of January 2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number 001-39446</B></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CureVac N.V.</B></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Friedrich-Miescher-Strasse 15, 72076</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>T&uuml;bingen, Germany</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>+49 7071 9883 0</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Address of principal executive offices)
</B></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM 20-F&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FORM
40-F&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;<FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule
12g3-2(b) under the Securities Exchange Act of 1934:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">YES&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NO&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#120;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If &#8220;Yes&#8221; is marked, indicate
below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _______</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Advance Purchase Agreement for our COVID-19
Vaccine Candidate</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 30, 2020,
CureVac A.G. (the &#8220;Company&#8221;) entered into an advance purchase agreement, or APA, with the European Commission, or the
EC, acting on behalf and in the name of all Member States of the European Union. The APA provides for the advance purchase by the
Member States of 225 million doses of the Company&#8217;s COVID-19 vaccine candidate, or CVnCoV, to be allocated among the Member
States, and the option to purchase up to an additional 180 million doses. The option may be exercised by the EC on behalf and in
the name of the Member States. In order to support the Company&#8217;s accelerated efforts to develop a safe and effective vaccine,
the APA provides for support to the Company&#8217;s operation in the form of two up-front payments. The first up-front payment
of a mid nine-figure euro amount has already been paid by the EC on behalf of the Member States. The second up-front payment of
a mid nine-figure euro amount is to be paid directly by the Member States and is due after an interim data package has been submitted
by the Company to the EMA for the purpose of obtaining EU marketing authorization for CVnCoV. Such up-front payments must be used
solely for the development and commercial supply of CVnCoV. The Company will be required to return any unspent amounts of the up-front
payments if, among others, the Company fails to successfully develop CVnCoV or if the Company successfully develops CVnCoV, but
the Company does not receive EU marketing authorization or fails to supply any doses of CVnCoV to any of the Member States by late
2021, unless the Company and the EC mutually agree to a later date. In addition, if any Member State decides to purchase additional
doses pursuant to the option granted under the APA, the Company will be entitled to additional up-front payments that are not subject
to such restrictions on use or return of unused amounts upon termination of the APA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company currently estimates the total
value of the APA to be in the low 10-figure euro amount assuming no exercise of the option discussed above, but this estimate is
subject to the Company&#8217;s ability to successfully deliver CVnCoV pursuant to the terms of the APA, including obtaining EU
marketing authorization and establishing manufacturing capacities to supply sufficient quantities of CVnCoV.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information in this Form 6-K (including
Exhibit 99.1) shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934 (the &#8220;Exchange
Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing
under the Securities Act of 1933 or the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">CUREVAC N.V.</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="width: 50%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 3%; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">By:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 47%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/&nbsp;Franz-Werner&nbsp;Haas,&nbsp;LLD,&nbsp;LLM</FONT></TD>
    </TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt"><I>Chief Executive Officer</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: January 19, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT INDEX</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; width: 10%; text-align: center"><FONT STYLE="font-size: 10pt">EXHIBIT NO.</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: left; width: 88%"><FONT STYLE="font-size: 10pt">DESCRIPTION</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Advance Purchase Agreement by and between CureVac A.G. and the European Commission, dated November 30, 2020.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm213031d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><B>REDACTED</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material
and (ii) would likely cause competitive harm if publicly disclosed.</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">[Contract Number]</P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0; width: 100%">
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.8in; text-align: left">&nbsp;<IMG SRC="tm213031d1_10-ximg014.jpg" ALT=""></TD>
<TD STYLE="text-align: justify">EUROPEAN <I>COMMISSION<BR>
</I>Directorate-General for Health and Food Safety &nbsp;</TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.95pt; text-align: center">ADVANCE PURCHASE AGREEMENT (&ldquo;<B><I>APA</I></B>&rdquo;)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP></FONT>
for the development, production, advance purchase and supply of a COVID-19 vaccine for EU Member States</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 33.25pt; text-align: center">NUMBER &mdash; <FONT STYLE="background-color: #D2D2D2"><B>SANTE/2020/C3/049</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The European Commission (the &ldquo;<B>Commission</B>&rdquo;), acting on behalf and in the name of the Member States listed
in <B><U>Annex I</U></B> (the &ldquo;<B>participating Member State(s)</B>&rdquo;)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2</SUP></FONT>
being represented for the purposes of the signature of this <I>APA</I> by Ms Stella Kyriakides, Commissioner for Health and Food
Safety</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <B>CUREVAC AG, </B>Friedrich-Miescher-Str. 15, 72076 T&uuml;bingen, Deutschland, HRB 754041, Stuttgart District Court,
DE 221 393 632,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15.9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(the &ldquo;<B>contractor</B>&rdquo;),
represented for the purposes of the signature of this <I>APA</I> which has the form of a framework contract by [<FONT STYLE="background-color: #D2D2D2"><I>forename,
surname, function of legal representative</I></FONT>],</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Commission, acting on behalf and in
the name of the <I>participating Member States</I>, and the <I>contractor</I> are together referred to as the &ldquo;<B>Parties</B>&rdquo;
and each individually as a &ldquo;<B>Party</B>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">HAVE AGREED</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">to the <B>special conditions
and the general conditions of this <I>APA</I></B> and the following annexes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in; width: 13%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Annex I &ndash;</B></FONT></TD>
    <TD STYLE="width: 87%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">List of <I>participating Member States</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Annex II &ndash;</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Template <I>Vaccine Order Form </I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Annex III &ndash; </B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annex 7 to <I>Commission
</I>Decision C(2020) 4192 final of 18 June 2020 - Agreement between the <I>Commission</I> and Member States on procuring COVID-19
vaccines on behalf of the Member States and related procedures</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Annex IV &ndash; </B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preliminary <I>Specification</I> of the <I>Product</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Annex V &ndash; </B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">List of (planned) manufacturing network partners </FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15.9pt; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15.9pt; text-align: justify"><FONT STYLE="font-size: 1pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP></FONT></TD><TD STYLE="text-align: justify">This APA is based on the agreement between the <I>Commission</I> and the Member States as approved
by <I>Commission</I> Decision C(2020) 4192 final on approving the agreement with Member States on procuring Covid-19 vaccines on
behalf of the Member States and related procedures.</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2</SUP></FONT></TD><TD STYLE="text-align: justify">As provided for in Article 4(5)(b) of Council Regulation (EU) 2016/369 of 15 March 2016 on the
provision of emergency support within the Union as amended by Council Regulation (EU) 2020/521 of 14 April 2020 activating the
emergency support under Regulation (EU) 2016/369, and amending its provisions taking into account the COVID-19 outbreak.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15.9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15.9pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15.9pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in; text-align: justify; width: 13%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Annex VI &ndash; </B></FONT></TD>
    <TD STYLE="text-align: justify; width: 87%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Template <I>Goods Received Form</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Annex VII &ndash; </B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of the <I>contractor</I>'s intended utilisation of the <I>up-front payment</I> and the <I>second up-front payment</I></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">which form an integral part
of this <I>APA</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>



<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Recitals</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.25in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15.9pt"></TD><TD STYLE="width: 40.8pt">A.</TD><TD STYLE="text-align: justify">The world is experiencing an emergency healthcare crisis due to the SARS-CoV-2 (&ldquo;<B><I>COVID-19</I></B>&rdquo;)
pandemic (the &ldquo;<B><I>COVID-19</I> pandemic</B>&rdquo;) and the global demand for vaccines to prevent <I>COVID-19</I> virus
infection is expected to be in order of magnitude of billions of doses.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -40.8pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15.9pt"></TD><TD STYLE="width: 40.8pt">B.</TD><TD STYLE="text-align: justify">The <I>contractor</I> and its <I>affiliates</I> are currently working to develop and manufacture
an mRNA-based vaccine to help protect against <I>COVID-19</I> virus infection in humans (the &ldquo;<B>Product</B>&rdquo; as further
defined below).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -40.8pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15.9pt"></TD><TD STYLE="width: 40.8pt">C.</TD><TD STYLE="text-align: justify">The <I>contractor</I>'s project for the development of the <I>Product</I> has completed dose selection
and is about to enter pivotal Phase IIB/III clinical trial studies towards regulatory submission. Furthermore, the <I>contractor</I>
is currently establishing its own and external manufacturing capacities in Europe through partnerships with experienced contract
manufacturing organisations (&ldquo;<B>CMOs</B>&rdquo;) in order to meaningfully contribute to controlling the <I>COVID-19 pandemic</I>.
While the <I>contractor</I> has prioritised and accelerated its efforts to develop and manufacture the <I>Product </I>in light
of the current <I>COVID-19 pandemic</I>, there is nonetheless substantial uncertainty around these efforts, in particular with
respect to (i) the clinical development of the <I>Product</I>, with respect to (ii) the <I>Product</I>'s ability to show sufficient
efficacy to prevent a <I>COVID-19</I> infection, with respect to (iii) the question whether the <I>Product</I> might have inacceptable
adverse event symptoms beyond what will be documented in the ongoing and planned clinical trials and with respect to (iv) obtaining
timely <I>EU marketing authorisation</I> for the <I>Product</I> as well as with respect to (v) the establishment of sufficient
production and manufacturing capacity.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -40.8pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15.9pt"></TD><TD STYLE="width: 40.8pt">D.</TD><TD STYLE="text-align: justify">The <I>Commission</I> intends to create the environment required to support a secure manufacturing
network and optimisation for the production of vaccines against <I>COVID-19</I>. To this effect the <I>Commission</I> has concluded
an agreement with all Member States of the European Union to conclude, on behalf and in the name of the Member States, Advance
Purchase Agreements with vaccine manufacturers with the objective to procure vaccines for the purposes of combatting the <I>COVID-19
pandemic</I> at Union level.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -40.8pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15.9pt"></TD><TD STYLE="width: 40.8pt">E.</TD><TD STYLE="text-align: justify">The <I>Commission</I> wishes to secure supply of the <I>Product</I> for human use for the <I>participating
Member States</I> during the COVID&#45;19 Pandemic as promptly as possible.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -40.8pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15.9pt"></TD><TD STYLE="width: 40.8pt">F.</TD><TD STYLE="text-align: justify">The intention of the <I>Commission</I>, on behalf of the <I>Member States</I>, is to ensure that
the population in the European Union will be able to access a vaccine in sufficient quantities and at a fair price, but also in
safe conditions. The vaccine should only be available to the population once its safety and efficacy will have been cleared by
the competent regulatory bodies.</TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15.9pt"></TD><TD STYLE="width: 40.8pt">G.</TD><TD STYLE="text-align: justify">According to the Agreement between the <I>Commission</I> and the Member States<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>3</SUP></FONT>
and in particular Article 4 thereof, the <I>Commission</I> can conclude an Advance Purchase Agreement that contains a right and
an obligation for participating Member States to acquire vaccine doses. Where the <I>Commission</I> intends to enter into such
an agreement, it shall inform the Member States of such intention and the detailed terms. In case a Member State does not agree
with the conclusion of an APA containing an obligation to acquire vaccine doses or its terms, it has the right to opt out by explicit
notification to the <I>Commission</I>. All <I>participating Member States</I> not having opted out in accordance with the Agreement
between the <I>Commission</I> and the Member States are deemed to have authorised the <I>Commission</I> to negotiate and conclude
an Advance Purchase Agreement with the vaccine manufacturer in their name and on their behalf.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -40.8pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15.9pt"></TD><TD STYLE="width: 40.8pt">H.</TD><TD STYLE="text-align: justify">This <I>APA</I> is such an agreement which the <I>Commission</I> enters into on behalf and in the
name of the Member States which have not opted out of the agreement. These <I>participating Member States</I> will then have an
obligation to acquire the <I>Product</I> and a right to be supplied with the respective <I>Product</I> doses. While the <I>APA</I>
is legally binding upon those <I>participating Member States</I>, it will be further implemented by means of the conclusion of
contracts between the <I>participating Member States</I> and the <I>contractor</I>. The present APA will be complemented by a <I>Vaccine
Order Form</I> (&ldquo;<B>Vaccine Order Form</B>&rdquo;) between each of the <I>participating Member States</I> and the <I>contractor</I>.
A template <I>Vaccine Order Form</I> for the agreement between each of the <I>participating Member States</I> and the <I>contractor</I>
is attached in Annex II.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -40.8pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15.9pt"></TD><TD STYLE="width: 40.8pt">I.</TD><TD STYLE="text-align: justify">The development, production, advance sale and supply of the <I>Product</I> as per this <I>APA</I>
require significant investments by the <I>contractor</I> to increase the speed of vaccine research and development and clinical
trials and the preparation of the at-scale production capacity along the entire production value chain in the EU required for a
rapid deployment of the millions of <I>doses</I> of the <I>Product</I>. The <I>Commission</I> as well as the <I>participating Member
States</I> are willing to contribute to financing of those investments in the form of up-front payments.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -40.8pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15.9pt"></TD><TD STYLE="width: 40.8pt">J.</TD><TD STYLE="text-align: justify">Pursuant to these terms and conditions, access to <I>Product doses</I> will be allocated to Member
States according to a population distribution key, unless a different allocation would be communicated by the <I>Commission</I>
to the <I>contractor</I>. The up-front payments, paid by the <I>Commission</I>, should be taken into account in equal terms per
<I>dose </I>ordered by the Member States.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -40.8pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15.9pt"></TD><TD STYLE="width: 40.8pt">K.</TD><TD STYLE="text-align: justify">The <I>Parties</I> recognise that the accelerated development timelines to deliver the clinical
trial and follow-up programme agreed with EMA means that the <I>contractor</I> under no circumstance can warrant, or assume any
liability, at the time of entry into force of this <I>APA</I> that the <I>Product</I> will be ultimately available or will produce
the desired results, i.e. shows sufficient efficacy to prevent a <I>COVID-19</I> infection, or be without inacceptable side effects.
The <I>participating Member States</I> are willing to share those risks, which includes an obligation of the <I>participating
Member States</I> to indemnify the <I>contractor </I>and its CMOs in case of liability incurred, settlements paid and certain costs
relating to third party claims with respect to those risks under the conditions set out in this <I>APA</I>. The <I>Commission</I>
and <I>participating Member States</I> acknowledge that the use of <I>Products</I> will happen under epidemic conditions requiring
such use, and that the administration of the <I>Product</I> will therefore be conducted under the sole responsibility of the <I>participating
Member States</I>.</TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 1pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="font-family: Times New Roman, Times, Serif; width: 28.35pt"><FONT STYLE="font-size: 10pt"><SUP>3</SUP></FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify">Such agreement is based on Article 4(5)(b) of Regulation (EU) 2016/369 of 15 March 2016 on the provision of emergency
support within the Union, OJ L 70, 16.3.2016, p.1, as amended by Council Regulation (EU) 2020/521 of 14 April 2020 activating
the emergency support under Regulation (EU) 2016/369, and amending its provisions taking into account the COVID-19 outbreak, OJ
L 117, 15.4.2020, p. 3. The agreement was approved Decision C(2020) 4192 final of 18 June 2020 (see Annex III to this <I>APA</I>).</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15.9pt"></TD><TD STYLE="width: 40.8pt">L.</TD><TD STYLE="text-align: justify">The <I>participating Member States</I> acknowledge that, in light of the uncertainties both with
respect to the development of the <I>Product</I> and the accelerated establishment of sufficient manufacturing capacities, the
delivery dates set out in this <I>APA</I> are the <I>contractor</I>'s current best estimates only and subject to change. Due to
possible delays in the authorisation, production and release of the <I>Product</I>, no <I>Product</I> or only reduced volumes of
the <I>Product</I> may be available at the estimated delivery dates set out in this <I>APA</I>. In the case of delays to the anticipated
availability of the <I>Product</I>, the <I>contractor</I> aims to allocate the <I>doses</I> of the <I>Product</I> fairly across
the demand of <I>doses</I>, which the <I>contractor</I> has or will contractually commit to towards its present and future customers,
as such <I>doses</I> become available.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -40.8pt"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15.9pt"></TD><TD STYLE="width: 40.8pt">M.</TD><TD STYLE="text-align: justify">The <I>participating Member States</I> further acknowledge that the <I>specification</I> of the
<I>Product</I> has not yet been fully determined and still contains target specifications, which are being refined as supporting
data emerges. In particular, the vaccination regimen ([*****]) and product
shelf-life and stability profile ([*****]) have not yet been fully established.
Also, the final presentation of the <I>Product</I> is still under consideration. The preliminary <I>specification</I> provided
in Annex IV to this <I>APA</I> is therefore only indicative. The final <I>specification</I> will be determined by the <I>EU marketing
authorisation</I>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -40.8pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 15.9pt"></TD><TD STYLE="width: 40.8pt"><FONT STYLE="font-size: 10pt">N.</FONT></TD><TD STYLE="text-align: justify">Against this background, the <I>Commission</I> wishes to enter into, on behalf and in the
                                                                                                     name of the <I>participating Member States</I>, an Advance Purchase Agreement with the <I>contractor </I>to secure the
                                                                                                     availability of a total of 225 million <I>doses</I> of the <I>Product</I>, to be allocated among the <I>participating Member
                                                                                                     States</I> in accordance with the allocation principles set out in this <I>APA</I>. The <I>Commission</I>, on behalf and in
                                                                                                     the name of the <I>participating Member States</I>, shall furthermore have the option to order up to a total of 180 million
                                                                                                     additional <I>doses</I> of the <I>Product</I> within [*****] from the <I>contractor</I> obtaining (conditional) <I>EU
                                                                                                     marketing authorisation</I>, subject to the terms and conditions of this <I>APA</I>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -40.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15.9pt; text-align: justify">This <I>APA</I> sets out:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15.9pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">a.</TD><TD STYLE="text-align: justify">the procedure and conditions by which the <I>Commission</I> and the <I>participating Member States</I>
shall pay for the purchase from and supply of the <I>Product</I> by the <I>contractor</I>;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">b.</TD><TD STYLE="text-align: justify">the supply obligations of the <I>contractor</I> for the <I>Product</I> and the estimated delivery
schedule;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">c.</TD><TD STYLE="text-align: justify">the provisions that apply to any <I>Vaccine Order Form</I> which the <I>participating Member States</I>
and the <I>contractor</I> may conclude under this <I>APA</I>; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 53.95pt"></TD><TD STYLE="width: 18.05pt">d.</TD><TD STYLE="text-align: justify">the obligations of the <I>Parties</I> during and after the duration of this <I>APA</I>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15.9pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><U>TABLE OF CONTENTS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">Recitals</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right; padding-bottom: 4pt">2</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; text-transform: uppercase">
    <TD COLSPAN="3" STYLE="padding-top: 4pt; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">TABLE OF CONTENTS</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; text-align: right; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">5</FONT></TD></TR>

<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-top: 4pt; font-size: 10pt; text-transform: uppercase; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-top: 4pt; font-size: 10pt; text-transform: uppercase; padding-bottom: 4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Special Conditions</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; text-align: right; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">7</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-top: 4pt; width: 3%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt; width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.1.</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Order of priority of provisions</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; text-align: right; padding-bottom: 4pt; width: 5%"><FONT STYLE="font-size: 10pt">7</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.2.</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitions</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; text-align: right; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">7</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.3.</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject matter</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; text-align: right; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">10</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.4.</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entry into force and duration of the APA</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; text-align: right; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">11</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.5.</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Implementation of the APA</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; text-align: right; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">11</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.6.</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; text-align: right; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">12</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.7.</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract Volume</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; text-align: right; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">13</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.8.</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allocation and Vaccine Order Forms</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; text-align: right; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">13</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.9.</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Development Timeline; Special Commitments</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; text-align: right; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">14</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.10.</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right of the participating Member States to
    re-sell, export and/or distribute the Product</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; text-align: right; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">15</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.11.</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delivery; Estimated Delivery Schedule; Delays</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; text-align: right; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">16</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.12.</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delays</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; text-align: right; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">17</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.13.</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Packaging; Labelling</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; text-align: right; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">17</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.14.</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warranties; Acceptance mechanism</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; text-align: right; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">18</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.15.</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product recalls</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; text-align: right; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">19</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.16.</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price of the Product</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; text-align: right; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">19</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.17.</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment obligations</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; text-align: right; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">20</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.18.</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contractor's bank account</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; text-align: right; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">21</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.19.</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Communication details</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; text-align: right; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">22</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.20.</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exploitation of the results of the APA</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; text-align: right; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">22</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.21.</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applicable law and settlement of disputes</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; text-align: right; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">22</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.22.</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reporting</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; text-align: right; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">23</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.23.</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnification</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; text-align: right; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">23</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-top: 4pt; font-size: 10pt; text-transform: uppercase; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">II.</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-top: 4pt; font-size: 10pt; text-transform: uppercase; padding-bottom: 4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">GENERAL CONDITIONS</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; text-align: right; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">26</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">II.1.</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severability</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; text-align: right; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">26</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">II.2.</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provision of Supplies</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; text-align: right; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">26</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">II.3.</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Communication between the parties</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; text-align: right; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">26</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">II.4.</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liability</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; text-align: right; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">27</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">II.5.</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conflict of interest and professional conflicting
    interests</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; text-align: right; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">27</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">II.6.</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidentiality and public announcements</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; text-align: right; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">28</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-top: 4pt">&nbsp;</TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">II.7.</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Processing of personal data</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">29</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="width: 3%; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-bottom: 4pt; width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">II.8.</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-bottom: 4pt; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subcontracting</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right; padding-bottom: 4pt; width: 5%"><FONT STYLE="font-size: 10pt">29</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">II.9.</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendments</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; text-align: right; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">29</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">II.10.</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assignment</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; text-align: right; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">30</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">II.11.</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Force majeure</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; text-align: right; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">30</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">II.12.</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reduction in price</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; text-align: right; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">30</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">II.13.</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suspension of the APA</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; text-align: right; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">31</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">II.14.</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination of the APA</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; text-align: right; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">32</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">II.15.</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment Requests, Invoices, Value Added Tax
    and e-invoicing</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; text-align: right; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">35</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-top: 4pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">II.16.</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; text-align: right; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">35</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="padding-top: 4pt">&nbsp;</TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">II.17.</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Checks and audits</FONT></TD>
    <TD STYLE="padding-top: 4pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">37</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 95%; text-transform: uppercase; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none"><B>Annex
    I&nbsp;&nbsp; List of participating Member States</B></FONT></TD>
    <TD STYLE="text-align: right; width: 5%; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">40</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4pt; text-transform: uppercase; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none"><B>Annex
    II&nbsp;&nbsp; Template Vaccine Order Form</B></FONT></TD>
    <TD STYLE="padding-top: 4pt; text-align: right; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">41</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.4in; padding-top: 4pt; text-transform: uppercase; padding-bottom: 4pt; text-indent: -0.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none"><B>Annex
    III&nbsp;&nbsp; Annex 7 to Commission Decision C(2020) 4192 final of 18 June 2020 - Agreement between the Commission and Member
    States on procuring COVID-19 vaccines on behalf of the Member States and related procedures</B></FONT></TD>
    <TD STYLE="padding-top: 4pt; text-align: right; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">45</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4pt; text-transform: uppercase; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none"><B>Annex
    IV&nbsp;&nbsp; Preliminary Specification of the Product</B></FONT></TD>
    <TD STYLE="padding-top: 4pt; text-align: right; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">52</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4pt; text-transform: uppercase; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none"><B>Annex
    V&nbsp;&nbsp; List of (planned) manufacturing network partners</B></FONT></TD>
    <TD STYLE="padding-top: 4pt; text-align: right; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">53</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4pt; text-transform: uppercase; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none"><B>Annex
    VI&nbsp;&nbsp; Goods Received Form </B></FONT><FONT STYLE="font-size: 10pt; text-transform: none">(preliminary)</FONT></TD>
    <TD STYLE="padding-top: 4pt; text-align: right; padding-bottom: 4pt"><FONT STYLE="font-size: 10pt">54</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4pt; text-transform: uppercase"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none"><B>Annex
    VII&nbsp;&nbsp; Description of the contractor's intended utilisation of the up-front payment and the second up-front payment</B></FONT></TD>
    <TD STYLE="padding-top: 4pt; text-align: right"><FONT STYLE="font-size: 10pt">56</FONT></TD>
    </TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="text-align: center; font: small-caps bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> I.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">Special Conditions</U></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 141.75pt"></TD><TD STYLE="width: 32.4pt"><FONT STYLE="font-variant: normal">I.1.</FONT></TD><TD>Order of priority of provisions</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If there is any conflict between different
provisions in this <I>APA</I>, the following rules must be applied:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.6pt"></TD><TD STYLE="width: 30.25pt">(a)</TD><TD STYLE="text-align: justify">The provisions set out in the special conditions take precedence over those in the other parts
of this <I>APA</I>, including all annexes.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.6pt"></TD><TD STYLE="width: 30.25pt">(b)</TD><TD STYLE="text-align: justify">The provisions set out in the special conditions and the general conditions (including all annexes
other than Annexes II and VI) take precedence over those in the template <I>Vaccine Order Form</I> (Annex II) and in any <I>Vaccine
Order Form</I> concluded between a <I>participating Member State</I> and the <I>contractor</I>.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.6pt"></TD><TD STYLE="width: 30.25pt">(c)</TD><TD STYLE="text-align: justify">The provisions set out in the special conditions and the general conditions (including all annexes
other than Annex VI) take precedence over Annex VI.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 51.85pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All documents issued by the <I>contractor</I>
(such as end-user agreements, general terms and conditions, etc.) are held inapplicable, unless they are issued under or in accordance
with this <I>APA</I> (such as the <I>final specifications</I>, (<I>formal</I>) <I>notifications</I>, etc.). In all circumstances,
in the event of contradiction between this <I>APA</I> and documents issued by the <I>contractor</I>, this <I>APA</I> prevails,
regardless of any provision to the contrary in the <I>contractor</I>&rsquo;s documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 141.75pt"></TD><TD STYLE="width: 32.4pt"><FONT STYLE="font-variant: normal">I.2.</FONT></TD><TD>Definitions</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the purpose of this <I>APA</I>, the
following definitions (indicated in <I>italics </I>in the text) apply:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&lsquo;Additional Doses up-front payment&rsquo;</B>:
the up-front payment relating to the <I>Additional European Doses</I> as specified in Article I.17.2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&lsquo;Additional European Doses&rsquo;</B>:
the additional number of <I>doses</I>, which may be ordered by the <I>Commission</I> in accordance with Article I.7.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&lsquo;Affiliate&rsquo;</B>: any
company, partnership or other entity that controls, is controlled by, or is under common control with the <I>contractor</I>.
For purposes of this definition only, &quot;control&quot; means (a) to possess, directly or indirectly, the power to direct
the management or policies of an entity, whether through ownership of voting securities, by contract relating to voting
rights or corporate governance or otherwise, or (b) to own, directly or indirectly, more than 50 % of the outstanding voting
securities or other ownership interest of such entity, provided that, if applicable law requires a minimum percentage of
local ownership, control will be established by direct or indirect beneficial ownership of 100 % of the maximum ownership
interest that may, under such applicable law, be owned by foreign interests, provided, however, that regarding the <I>contractor</I>,
the term affiliate shall not include [*****], [*****] and/or any other companies controlled by [*****] and/or [*****] that
are not subsidiaries of the <I>contractor</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&lsquo;Apparent defect&rsquo;</B>: any
defect of the <I>Product</I> existent at the moment of delivery at the <I>delivery site</I> of the relevant <I>participating Member
State</I> that has been identified or could have been identified upon visual inspection of the pallet or grouping box of the <I>Product
</I>or the temperature monitoring device. It may include a physical damage, a leakage, an incorrect labelling or temperature readings
or recordings that deviate from the required cold chain specifications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&lsquo;Breach of obligations&rsquo;</B>:
failure by the <I>contractor</I> to fulfil one or more of its contractual obligations, unless the <I>APA</I> (i) states explicitly
that the non-fulfilment of an obligation shall not result in any consequences or (ii) provides for a specific consequence other
than those set forth in Article II.14.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&lsquo;CMO&rsquo;</B>: a contract manufacturing
organisation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&lsquo;Commission&rsquo;</B>: the European
Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&lsquo;Confidential information or document&rsquo;</B>:
any information or document disclosed or given between the <I>Parties</I> or on their behalf in the context of the negotiation
and conclusion of the <I>APA</I> (including the terms of the <I>APA</I> and the <I>Vaccine Order Forms</I>) and/or the performance
of the <I>APA</I>. It does not include any information (i) the receiving <I>Party</I> can prove was known to it prior to the date
of disclosure; (ii) the receiving <I>Party</I> can prove was lawfully obtained from a third party without any obligation of confidentiality;
(iii) is or becomes part of the public domain other than through any act or omission of the receiving <I>Party</I>; or (iv) is
independently developed by the receiving <I>Party</I> without use of or reference to the disclosing <I>Party</I>&rsquo;s <I>confidential
information or documents</I>, as evidenced by the receiving <I>Party</I>&rsquo;s records.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&lsquo;Conflict of interest&rsquo;</B>:
a situation where the impartial and objective performance of this <I>APA</I> by the <I>contractor</I> is compromised for reasons
involving family, emotional life, political or national affinity, economic interest, any other direct or indirect personal interest,
or any other shared interest with the <I>Commission</I>, the <I>participating Member State</I> or any third party related to the
subject matter of this <I>APA</I>, it being understood that the conclusion, implementation and performance of further agreements
on the provision of the <I>Product</I> shall not constitute a <I>conflict of interest</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&lsquo;Contractor&rsquo;</B>: CUREVAC
AG with its seat in T&uuml;bingen, registered with the commercial register of the local court of Stuttgart under HRB 754041.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&lsquo;<I>COVID-19</I> pandemic&rsquo;</B>:
the pandemic as further described in the Recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&lsquo;Delivery site(s)&rsquo;</B>:
the delivery site as indicated in the relevant <I>Vaccine Order Form</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&lsquo;Dose&rsquo;:</B> the amount of
the <I>Product </I>as specified in Article I.6.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&lsquo;EMA&rsquo;</B>: the European
Medicines Agency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&lsquo;EU marketing authorisation&rsquo;</B>:
the approval under the relevant provisions of Regulation (EC) 726/2004 of the European Parliament and of the Council of 31 March
2004 laying down Union procedures for the authorisation and supervisions of medicinal products for human and veterinary use and
establishing a European Medicines Agency, by the European Commission necessary for the placing on the market of the <I>Product</I>
for vaccination in the territory of the European Union, including conditional marketing authorisation in accordance with Article
14-a of Regulation 726/2004 and Commission Regulation 507/2006/EC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&lsquo;Final specification&rsquo;</B>:
the final specification of the <I>Product</I> as to be determined by <I>contractor</I> in accordance with in Article I.6.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&lsquo;Force majeure&rsquo;</B>: any
unforeseeable, exceptional situation or event beyond the control of the <I>Parties</I> that prevents either of them from fulfilling
any of their obligations under the <I>APA</I>. The situation or event must not be attributable to error or negligence on the part
of the <I>Parties</I> or on the part of the subcontractors and must prove to be inevitable despite their exercising due diligence.
Defaults of service, defects in equipment or material or delays in making them available, labour disputes, strikes and financial
difficulties may not be invoked as <I>force majeure</I>, unless they are caused by a relevant case of <I>force majeure</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&lsquo;Formal notification&rsquo; </B>(or
 &lsquo;<B>formally notify</B>&rsquo;): form of communication between the <I>Parties</I> made in writing by mail or e-mail in English,
which provides the sender with compelling evidence that the message was delivered to the specified recipient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&lsquo;Fraud&rsquo;</B>: an act or omission
committed in order to make an unlawful gain for the perpetrator or another by causing a loss to the Union's financial interests,
and relating to: i) the use or presentation of false, incorrect or incomplete statements or documents, which has as its effect
the misappropriation or wrongful retention of funds or assets from the Union budget, ii) the non-disclosure of information in violation
of a specific obligation, with the same effect or iii) the misapplication of such funds or assets for purposes other than those
for which they were originally granted, which damages the Union's financial interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&lsquo;GDP&rsquo;</B>: good distribution
practices in accordance with standards currently required by EU legislation, regulation and guidance, in particular those set out
in its Guidelines of 5 November 2013 on Good Distribution Practice of medicinal products for human use published by the European
Commission (2013/C 343/01) and other applicable regulation pertaining to distribution practices throughout the supply chain, all
as updated, amended and revised from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&lsquo;GMP&rsquo;</B>: good manufacturing
practices in accordance with standards currently required by EU legislation, regulation and guidance and in particular those set
out in Directive 2001/83/EC (as amended), Directive 2003/94/EC, Directive 2017/1572 and the guidelines set out in EudraLex - Volume
4 of the Rules Governing Medical Products in the European Union entitled &ldquo;Good Manufacturing Practice (GMP)&rdquo;, all as
updated, amended and revised from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&lsquo;Goods Received Form&rsquo;</B>:
acknowledgement of receipt of the <I>Products</I> in the form of the template attached as Annex VI to be issued by the <I>participating
Member States</I> as specified in Article I.14.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&lsquo;Grave professional misconduct&rsquo;</B>:
a violation of applicable laws or regulations or ethical standards of the profession to which a contractor or a related person
belongs, including any conduct leading to sexual or other exploitation or abuse, or any wrongful conduct of the <I>contractor</I>
or a related person which has an impact on its professional credibility where such conduct denotes wrongful intent or gross negligence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&lsquo;Hidden defect&rsquo;</B>: a physical
damage or product manufacturing defect of the <I>Product</I> that does not qualify as an <I>apparent defect</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&lsquo;Indemnified Person(s)&rsquo;</B>:
the persons specified as <I>Indemnified Persons</I> in Article I.23.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&lsquo;Initial European Doses&rsquo;</B>:
the initial number of <I>doses</I> as specified in Article I.7.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&lsquo;Irregularity&rsquo;</B>: any
infringement of a provision of Union law resulting from an act or omission by an economic operator, which has, or would have, the
effect of prejudicing the Union&rsquo;s budget.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&lsquo;Loss(es)&rsquo;</B>: any harm,
damage or loss as specified in Article I.23.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&lsquo;Notification&rsquo; </B>(or &lsquo;notify&rsquo;):
form of communication between the <I>Parties</I> made in writing in English, including by electronic means.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&lsquo;Participating Member States&rsquo;</B>:
the Member States listed in Annex I.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&lsquo;Party&rsquo; </B>(or <B>&lsquo;Parties&rsquo;</B>):
the persons specified as <I>Parties </I>in the beginning of this Agreement..</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&lsquo;Performance of a <I>Vaccine Order
Form</I>&rsquo;</B>: the delivery of the <I>Product</I> by the <I>contractor</I> to the <I>participating Member State</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&lsquo;Product&rsquo;</B>: the pandemic
<I>COVID-19</I> vaccine as specified in Article I.6.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&lsquo;Product IP Rights&rsquo;</B>:
the intellectual property rights generated during the development, manufacture, and supply of the <I>Product</I>, including know-how,
as specified in Article I.20.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&lsquo;Product Price&rsquo;</B>: the
price for the <I>Product</I> per <I>dose </I>as specified in Article I.16.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&lsquo;Professional conflicting interest&rsquo;</B>:
a situation in which the <I>contractor</I>&rsquo;s previous or ongoing professional activities affect its capacity to implement
this <I>APA</I> or to perform a <I>Vaccine Order Form</I> to an appropriate quality standard, it being understood that the conclusion,
implementation and performance of further agreements on the provision of the <I>Product</I> shall not constitute a <I>professional
conflicting interest</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&lsquo;Related person&rsquo;</B>: any
natural or legal person who is a member of the administrative, management or supervisory body of the <I>contractor</I>, or who
has powers of representation, decision or control with regard to the <I>contractor</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&lsquo;Reasonable best efforts&rsquo;</B>:
a reasonable degree of best effort to accomplish a given task, acknowledging that such things as, without limitation, the complex
and highly regulated nature of the <I>Product</I>; the timely availability of raw materials, inventories and liquid funds; yield
of process; the success of necessary clinical trials programs to support safety and immunogenicity data for the <I>Product</I>;
the approval of the final <I>Product</I> formulation; <I>contractor</I>'s commitments to other purchasers of the <I>Product</I>;
other reasons relating to the uncertainties of producing a new vaccine for a new disease with an mRNA platform for which vaccines
have not yet been registered by regulatory authorities; and any other currently unknown factors which may delay or render impossible,
<I>contractor</I>'s successful completion of the particular task, including without limitations, developing a suitable production
process as may be required for a new strain of virus, ramping up capacity at contract manufacturing partners, meeting delivery
schedules and obtaining the <I>EU marketing authorisation</I> may be beyond the complete control of the <I>contractor</I>, provided,
however, that the <I>contractor</I> shall not be required to take any actions inconsistent with past practice, ordinary course
of business, prudent and reasonable business behaviour and/or the <I>contractor</I>'s budget plannings at the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&lsquo;Result&rsquo;</B>: any intended
outcome of the implementation of the <I>APA</I>, whatever its form or nature. A <I>result </I>may be further defined in this <I>APA</I>
as a deliverable. A <I>result </I>may, in addition to newly created materials produced specifically for the <I>participating Member
States</I> by the <I>contractor</I> or at its request, also include pre-existing materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&lsquo;Second up-front payment&rsquo;</B>:
the further up-front payment as specified in Article I.17.2(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&lsquo;Specific deliveries&rsquo;</B>:
the delivery terms under the <I>Vaccine Order Form</I> as specified in Article I.8.4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&lsquo;Temporary national authorisation&rsquo;</B>:
the temporary distribution authorisation granted by the relevant <I>participating Member State</I> in accordance with national
laws and Article 5&nbsp;(2) of Directive 2001/83/EC of the European Parliament and of the Council of 6&nbsp;November 2001 on the
Community code relating to medicinal products for human use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&lsquo;Third Party Claim&rsquo;</B>:
any damages claim brought against any of the <I>Indemnified Persons</I> as specified in Article I.23.9.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&lsquo;Up-front payment&rsquo;</B>:
the up-front payment specified in Article I.17.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&lsquo;Vaccine Order Form&rsquo;</B>:
a contract concluded between the <I>contractor</I> and a <I>participating Member State</I>, substantially in the form of Annex
II as attached to this <I>APA</I>, specifying details of the <I>delivery site</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 141.75pt"></TD><TD STYLE="width: 32.4pt"><FONT STYLE="font-variant: normal">I.3.</FONT></TD><TD>Subject matter</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The subject of this <I>APA</I> is the
advance purchase of 225 million <I>doses</I> of the <I>Product</I>, as defined below in Article I.6, to be allocated among
the <I>participating Member States</I> by the <I>Commission</I> in accordance with the allocation principles set out below in
Article I.8.1. Additionally, this <I>APA</I> gives the <I>Commission</I> the option to order, on behalf and in the name of
the <I>participating Member States</I>, up to&nbsp;180 million additional <I>doses</I> of the <I>Product</I> once <I>EU
marketing authorisation</I> has been granted, such additional <I>doses</I> to be allocated between the <I>participating
Member States</I> by the <I>Commission </I>as set out below in Article I.8.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On the basis of this <I>APA</I>, the <I>contractor</I>
commits to use <I>reasonable best efforts</I> (i) to obtain <I>EU marketing authorisation</I> for the <I>Product</I> and (ii) to
establish sufficient manufacturing capacities to enable the manufacturing and supply of the contractually agreed volumes of the
<I>Product</I> to the <I>participating Member States</I> in accordance with the estimated delivery schedule set out below in Article&nbsp;I.11
once at least a conditional EU marketing authorisation has been granted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The delivery of the <I>Product</I> to the
individual <I>participating Member States, </I>which, without prejudice to Article I.6.2, shall in principle be subject to the
grant of at least a conditional EU marketing authorisation, shall be carried out in accordance with the terms and conditions of
this <I>APA</I> and in particular the allocation decision <I>formally notified</I> by the <I>Commission</I>, as well as the additional
detailed terms of delivery set out in the <I>Vaccine Order Forms</I> to be concluded between the <I>contractor</I> and the <I>participating
Member States</I> using the template <I>Vaccine Order Form</I> provided as Annex II to this <I>APA</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 141.75pt"></TD><TD STYLE="width: 32.4pt"><FONT STYLE="font-variant: normal">I.4.</FONT></TD><TD>Entry into force and duration of the APA</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.4.1.</B></TD><TD STYLE="text-align: justify">This <I>APA</I> enters into force on the date on which the <I>contractor</I> and the <I>Commission
</I>have signed it.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.4.2.</B></TD><TD STYLE="text-align: justify">This <I>APA</I> has a term of 24 months from the date of its entry into force. Its duration may
be extended if at the end of the term of 24 months not all of the <I>Initial European Doses</I> or <I>Additional European Doses</I>,
as the case may be, have been supplied. In such case, its duration will be extended until the delivery of all of the <I>Initial
European Doses</I> or all of the <I>Additional European Doses</I>, as the case may be.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.4.3.</B></TD><TD STYLE="text-align: justify">During the term of this <I>APA</I>, the <I>contractor</I> shall not enter into any agreements or
accept any commitments which would impede the <I>contractor</I>'s ability to fulfil its main performance obligations under this
<I>APA</I>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.4.4.</B></TD><TD STYLE="text-align: justify">The <I>participating Member States</I> and the <I>contractor</I> may not sign any <I>Vaccine Order
Form</I> after this <I>APA</I> expires.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 51.85pt; text-align: justify">Articles I.23 and II.6 shall
remain in full force and effect, and this <I>APA</I> continues to apply to all <I>Vaccine Order Forms</I> signed prior to its expiry,
even after the expiry of this <I>APA</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 51.85pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 141.75pt"></TD><TD STYLE="width: 32.4pt"><FONT STYLE="font-variant: normal">I.5.</FONT></TD><TD>Implementation of the APA</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This <I>APA</I> shall be implemented following
entry into force as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.5.1.</B></TD><TD STYLE="text-align: justify">Following entry into force of this <I>APA</I>, this <I>APA</I> is binding upon the <I>contractor</I>,
the <I>Commission</I> and all <I>participating Member States</I> on behalf and in the name of which the <I>Commission</I> has concluded
this <I>APA</I>, as identified in Annex&nbsp;I.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.5.2.</B></TD><TD STYLE="text-align: justify">Following entry into force of this <I>APA</I>, the <I>Commission</I> will determine the allocation
of the contractually agreed <I>doses</I> of the <I>Product</I> between the <I>participating Member States</I> in accordance with
the procedure set out below in Article I.8 and will <I>formally notify</I> this allocation to the <I>contractor</I>. The allocation
<I>formally notified</I> to the <I>contractor</I> by the <I>Commission</I> on behalf and in the name of the <I>participating Member
States</I> is binding upon all <I>participating Member
States</I>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.5.3.</B></TD><TD STYLE="text-align: justify">Each <I>participating Member State</I> and the <I>contractor</I> will conclude a <I>Vaccine Order
Form</I>, using the template <I>Vaccine Order Form</I> attached as Annex II to this <I>APA</I>, setting out the details of the
delivery of the <I>doses</I> of the <I>Product</I> allocated to the respective <I>participating Member State</I>. For the avoidance
of doubt, each <I>participating Member State</I> is obligated to purchase and pay for the <I>doses</I> contractually allocated
to it as <I>formally notified</I> by the <I>Commission</I> regardless of whether such <I>Vaccine Order Form</I> is concluded or
not. The general conditions and the special conditions under this <I>APA</I> shall apply to, and, pursuant to Article I.1, prevail
over, the <I>Vaccine Order Forms</I>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.5.4.</B></TD><TD STYLE="text-align: justify">Wherever this <I>APA</I> provides that certain rights enjoyed by the <I>participating Member States</I>
under the <I>APA</I> shall be exercised by the <I>Commission</I>, the <I>Commission</I> alone shall be entitled to notify the <I>contractor</I>
of the exercise of such rights. Such <I>notification</I> shall be binding upon all <I>participating Member States</I>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.5.5.</B></TD><TD STYLE="text-align: justify">Wherever this <I>APA</I> provides that certain <I>notifications</I> of the <I>contractor</I> shall
be issued to the <I>Commission</I>, such <I>notification</I> to the <I>Commission</I> shall bind all <I>participating Member State(s)</I>.
The <I>Commission</I> is acting on behalf and in the name of the <I>participating Member State</I>s in such cases.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.5.6.</B></TD><TD STYLE="text-align: justify">The foregoing Articles I.5.4 and I.5.5 shall not apply to the <I>Vaccine Order Forms</I>, unless
provided otherwise in the <I>APA</I> or the relevant <I>Vaccine Order Form</I>. The <I>Vaccine Order Forms</I> shall only be implemented,
performed and consummated by the <I>contractor</I> and the relevant <I>participating Member State</I> (but not the <I>Commission</I>).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 141.75pt"></TD><TD STYLE="width: 32.4pt"><FONT STYLE="font-variant: normal">I.6.</FONT></TD><TD>Product</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.6.1.</B></TD><TD STYLE="text-align: justify">The &quot;<B>Product</B>&quot; to be supplied by the <I>contractor</I> under this <I>APA</I> is
a pandemic preservative-containing mRNA-based CVnCoV <I>COVID-19</I> vaccine. More specifically, the mechanism of the technology
of the vaccine will be an mRNA-based vaccine coding for the full length pre fusion conformation stabilised version of the full
length spike (S) protein of SARS-CoV-2 virus.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.6.2.</B></TD><TD STYLE="text-align: justify">An indicative specification of the <I>Product</I> is provided in Annex IV to this <I>APA</I>. However,
due to the early stage of development of the <I>Product</I>, this specification is subject to change. The &quot;<B>final specification</B>&quot;
of the <I>Product</I> will be determined by the <I>contractor</I>'s documentation of the <I>Product</I> as approved in the <I>EU
marketing authorisation</I>. If a <I>participating Member State</I> should request delivery of the <I>Product</I> prior to the
grant of the <I>EU marketing authorisation</I> and if <I>contractor</I> accepts such request (where the withholding of such acceptance
is at the <I>contractor</I>'s discretion pursuant to Article&nbsp;I.7.1), the relevant specification of the <I>Product</I> will
be determined by the documentation submitted by the <I>contractor</I> as approved in the <I>temporary national authorisation</I>
granted by that <I>participating Member State</I>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.6.3.</B></TD><TD STYLE="text-align: justify">In the context of this <I>APA</I>, a &quot;<B>dose</B>&quot; of the <I>Product</I> refers to the
amount of vaccine, including diluent, needed for one injection; this amount corresponds to [*****], the dose which
is taken forward to the pivotal Phase III clinical trial.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.6.4.</B></TD><TD STYLE="text-align: justify">The <I>Product</I> will be provided in the form of [*****] that will require a [*****]. However, the packaging characteristics
                                                                       (final presentation) are still in consideration. The [*****] will likely be presented in
                                                                       [*****] boxes and the [*****].
                                                                       Packaging will also include [*****]. The injected volume for one <I>dose</I>
is expected to be 0.5 ml (after dilution).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 51.9pt; text-align: justify">It is expected that a vaccination
regimen will encompass [*****].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 51.9pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 141.75pt"></TD><TD STYLE="width: 32.4pt"><FONT STYLE="font-variant: normal">I.7.</FONT></TD><TD>Contract Volume</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.7.1.</B></TD><TD STYLE="text-align: justify">Subject to the grant of an <I>EU marketing authorisation</I>, the <I>contractor</I> agrees to supply
to the <I>participating Member States</I> a total of 225 million <I>doses</I> of the <I>Product</I> (the &ldquo;<B>Initial European
Doses</B>&rdquo;) in accordance with the estimated delivery schedule set out in Article&nbsp;I.11 below (as adjusted pursuant to
Article I.12, as the case may be). The <I>contractor</I> also agrees to supply to a <I>participating Member State</I> the relevant
portion of the <I>Initial European Doses</I> in accordance with the estimated delivery schedule set out in Article&nbsp;I.11 below
(as adjusted pursuant to Article I.12, as the case may be) if the <I>participating Member State</I> in question has granted a <I>temporary
national authorisation</I> and if the <I>contractor</I> accepts the supply on the basis of such <I>temporary national authorisation</I>,
it being understood that such acceptance may not be unreasonably withheld, provided, however, that the <I>contractor</I> may, inter
alia, reject its acceptance if it sees a potential risk of undermining the public's confidence (in the relevant country or more
broadly, in Europe given cross-border social media reach) in the safety and efficacy of potential vaccines without the approval
of the Commission.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.7.2.</B></TD><TD STYLE="text-align: justify">The <I>Commission</I> may, on behalf and in the name of the <I>participating Member States</I>,
place an additional order for up to 180 million <I>doses</I> of the <I>Product</I> by <I>formal notification </I>to the <I>contractor</I>
within [*****] following the grant of the <I>EU marketing authorisation</I> for the <I>Product</I> (the &ldquo;<B>Additional European
Doses</B>&rdquo;).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.7.3.</B></TD><TD STYLE="text-align: justify">The <I>Initial European Doses</I> and <I>Additional European Doses</I> correspond to the maximum
number of <I>doses</I> of the <I>Product</I> that the <I>contractor</I> is able to allocate to this <I>APA</I> in accordance with
the delivery schedule set out below in Article I.11.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.7.4.</B></TD><TD STYLE="text-align: justify">In addition to these contractually agreed volumes under this <I>APA</I>, the <I>contractor</I>
agrees to discuss in good faith any <I>participating Member State</I>&rsquo;s request to purchase additional quantities of the
<I>Product</I> after satisfying its contractual commitments to other partners and customers. Until the date that the <I>COVID-19
pandemic</I> is considered to be over, the <I>contractor</I> agrees [*****]; for this purpose, the <I>contractor</I> and the <I>participating Member State</I> concerned
will decide in good faith, taking into account expert advice, including the advice of the WHO, the date that the <I>COVID-19 pandemic</I>
is considered to be over. For the avoidance of doubt, any such additional quantities requested are subject to a separate agreement
between the <I>participating Member State</I> and the <I>contractor</I> outside the scope of this <I>APA</I>. For the avoidance
of doubt, the <I>contractor</I> shall not be required to enter into any such separate agreement or be held liable under this <I>APA</I>
for failure to enter into any such separate agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 174.15pt; text-indent: -0.45in"><FONT STYLE="font-variant: normal">I.8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>Allocation and Vaccine Order Forms</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 174.15pt; text-indent: -0.45in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.8.1.</B></TD><TD STYLE="text-align: justify">The <I>Initial European Doses</I> will be allocated by the <I>Commission</I> among the <I>participating
Member States</I> according to a population distribution key, unless a different allocation would be communicated by the <I>Commission</I>
to the <I>contractor</I>. The <I>contractor</I> will plan deliveries to each <I>participating Member
State</I> in accordance with the allocation key communicated by the <I>Commission</I> pursuant to the foregoing sentence. In order
to avoid too small deliveries which could put the supply chain at risk and increase complexity and costs of the deliveries, the
<I>Parties </I>agree that the minimum size per delivery will be the lower of either 1,000,000 <I>doses</I> or 12% of the total
number of <I>doses</I> allocated to the relevant <I>participating Member State</I> in accordance with the first sentence of this
Article.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.8.2.</B></TD><TD STYLE="text-align: justify">The <I>Commission</I> will <I>formally notify</I> to the <I>contractor</I> the volumes of the <I>Product</I>
allocated to each <I>participating Member State</I> under this <I>APA</I> within thirty (30) calendar days after entry into force
of this <I>APA</I>. This <I>formal notification</I> is binding upon all <I>Parties</I>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.8.3.</B></TD><TD STYLE="text-align: justify">The <I>Commission</I> will allocate the <I>Additional European Doses</I> between the <I>participating
Member States</I> in accordance with the principles set out above in Article I.8.1 and will <I>formally notify</I> the allocation
decision to the <I>contractor</I> within thirty (30) calendar days following its order of the <I>Additional European Doses</I>.
This <I>formal notification</I> is binding upon all <I>Parties</I>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.8.4.</B></TD><TD STYLE="text-align: justify">Following the <I>formal notification</I> of the allocation decision by the <I>Commission</I> pursuant
to Article I.8.2 or I.8.3 above, as the case may be, the <I>participating Member States</I> and the <I>contractor</I> will conclude
<I>Vaccine Order Forms</I> using the template <I>Vaccine Order Form</I> attached to this <I>APA</I> as Annex II. The purpose of
these <I>Vaccine Order Forms</I> is to specify further details of the delivery to the respective <I>participating Member State</I>,
such as the place of delivery (the &quot;<B>specific deliveries</B>&quot;). Each <I>Vaccine Order Form</I> shall be signed by the
relevant representative of the <I>participating Member State</I> and the <I>contractor</I>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify">The <I>participating Member
States</I> shall send the completed and duly signed <I>Vaccine Order Form</I> attached to this <I>APA</I> as Annex II, within fifteen
(15) calendar days after the <I>Commission formally notifies </I>to the <I>contractor </I>its allocation decision<I>. </I>The terms
of such <I>Vaccine Order Form</I>, in particular but without limitation, the volume stated therein, shall be aligned with &ndash;
and do not affect in any manner &ndash; the overall volumes, dates and phasing set forth in the delivery schedule set out in Article
I.11 below. Within ten (10) calendar days as of receipt of a <I>Vaccine Order Form</I> in compliance with the terms of this <I>APA</I>,
in particular the allocation decision of the <I>Commission</I> and the delivery schedule set out Article I.11 below, the <I>contractor</I>
will send back to the <I>participating Member States</I> the <I>Vaccine Order Form</I> duly signed and dated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 141.75pt"></TD><TD STYLE="width: 32.4pt"><FONT STYLE="font-variant: normal">I.9.</FONT></TD><TD>Development Timeline; Special Commitments</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.9.1.</B></TD><TD STYLE="text-align: justify">The <I>contractor</I> is currently concluding a dose escalating Phase I clinical trial for the
<I>Product </I>and is preparing recruitment and start of pivotal Phase IIb/III clinical trial studies. The <I>contractor</I> currently
anticipates that the rolling submission of the dossier to the EMA for <I>EU marketing authorisation</I> of the <I>Product</I> will
begin in [*****] and that conditional <I>EU marketing authorisation</I> may be granted within one or two months after submission,
based on anticipated accelerated EMA timelines. However, the <I>Parties</I> acknowledge that there is a risk that (i) a conditional
EU marketing authorisation may not be granted and that the placing of the <I>Product</I> on the market may instead require a full
EU marketing authorisation and that (ii) an <I>EU marketing authorisation</I> may not be granted at all.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.9.2.</B></TD><TD STYLE="text-align: justify">Subject to Article I.7.1, the delivery of the <I>Product</I> to the <I>participating Member States</I>
is in principle subject to prior grant of <I>EU marketing authorisation</I> for the <I>Product</I>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.9.3.</B></TD><TD STYLE="text-align: justify">The <I>contractor</I> commits to perform required clinical trials on specific relevant populations
such as the elderly, individuals with comorbidities and pediatric populations, as to be further discussed and agreed with EMA,
to obtain the <I>EU marketing authorisation</I>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>




<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: a1 -->
<P STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.9.4.</B></TD><TD STYLE="text-align: justify">To produce the <I>Initial European Doses</I>, the <I>contractor</I> may not manufacture or have
manufactured the <I>Product</I> at manufacturing sites located outside the territory of the European Union, the UK, the EEA or
Switzerland without the prior consent of the <I>Commission</I>, which consent may not be unreasonably withheld or delayed if the
manufacturing at such sites is required to accelerate the production of the <I>Initial European Doses</I>. The <I>CMOs</I> and
their manufacturing sites as identified in Annex V are deemed pre-approved.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-left: 1in; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-variant: normal">I.10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>Right of the participating Member States to re-sell, export and/or distribute the Product</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 161.85pt; text-indent: -32.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.10.1.</B></TD><TD STYLE="text-align: justify">The <I>participating Member States</I> will be entitled to re-sell, export and/or distribute any
of the <I>Products</I> supplied to them pursuant to this <I>APA</I> to any other EU or EEA Member State and Switzerland, provided
however that such re-sale, export and/or distribution may not take place before the concerned other EU or EEA Member State or Switzerland
expressly agrees in writing to fully assume the indemnity obligations as set out under Article I.23 below and to provide a formally
executed confirmation to the <I>contractor</I>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.10.2.</B></TD><TD STYLE="text-align: justify">The <I>participating Member States</I> shall take the appropriate measures to ensure that the <I>Products</I>
supplied to them pursuant to this <I>APA</I> will not be (i) re-sold or (ii) exported, distributed or donated for free to another
country outside the EU and EEA and Switzerland, including for donation via NGOs or the World Health Organization, without prior
consent of the <I>contractor</I>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.10.3.</B></TD><TD STYLE="text-align: justify">The <I>contractor</I> is free to grant or withhold its consent to a re-sale pursuant to Article
I.10.2 (i) at its own discretion, it being understood, however, that (i) no re-sale pursuant to Article&nbsp;I.10.2 (i) shall take
place at a price higher than the <I>Purchase Price</I> as agreed in this <I>APA</I> and (ii) no re-sale pursuant to Article I.10.2
(i) shall take place unless the receiving country first confirms to the satisfaction of the <I>contractor</I> (i) that it will
fully assume the indemnity obligations as set out under Article I.23 below or, alternatively, that there are other protection arrangements
that the <I>contractor</I> accepts as being adequate (such acceptance not to be unreasonably withheld) and (ii) that the indemnity
by the receiving country or other protection arrangement (as the case may be) is equivalent to the rights of the <I>contractor</I>
under Article I.23 below, both from a legal and commercial perspective. The <I>Parties</I> acknowledge that, should re-sale to
any third country, including EEA Member States and Switzerland, take place the <I>participating Member State</I> re-selling <I>doses</I>
has an obligation to reimburse the <I>Commission</I> the <I>up-front payment</I> per <I>dose</I> paid by the <I>Commission</I>
to the <I>contractor</I>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.10.4.</B></TD><TD STYLE="text-align: justify">The contractor shall not unreasonably withhold its consent to the export, distribution or donation
for free pursuant to Article I.10.2 (ii), it being understood, however, that no export, distribution or donation pursuant to Article
I.10.2 (ii) shall take place unless the receiving country first confirms to the satisfaction of the <I>contractor</I> (i) that
it will fully assume the indemnity obligations as set out under Article I.23 below or, alternatively, that there are other protection
arrangements that the <I>contractor</I> accepts as being adequate (such acceptance not to be unreasonably withheld) and (ii) that
the indemnity by the receiving country or other protection arrangement (as the case may be) is equivalent to the rights of the
<I>contractor</I> under Article I.23 below, both from a legal and commercial perspective.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.10.5.</B></TD><TD STYLE="text-align: justify">In addition, the <I>participating Member State</I> envisaging a re-sale, export, distribution or
donation pursuant to Articles I.10.1 or I.10.2 shall ensure, at its expense or at the expense of the receiving country, that the
required regulatory/quality/GMP/GDP processes to enable such re-sale, export, distribution or donation (i.e. for the transport
of the <I>Product</I> from the <I>participating Member State</I>
envisaging such re-sale, export, distribution or donation to the central warehouse of the receiving country) are in place, for
instance as pertains to (re)-labelling, validated transportation or cold chain integrity assurance. For the avoidance of doubt,
the <I>participating Member State</I> envisaging such re-sale, export, distribution or donation shall bear (or have the receiving
country bear) any liabilities, claims, costs (including costs for the transport of the <I>Product</I> from the <I>participating
Member State</I> envisaging such re-sale, export, distribution or donation to the central warehouse of the receiving country),
damages and other losses resulting from such re-sale, export, distribution or donation.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.10.6.</B></TD><TD STYLE="text-align: justify">In case of a donation or a re-sale to another EU or EEA Member State or Switzerland, the <I>contractor</I>
may, at its sole discretion and without incurring additional costs, attempt to support or execute implementation of regulatory/quality/GMP/GDP
requirements, particularly if the <I>Products</I> have not yet been delivered to the <I>participating Member State</I>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-left: -1.25in; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-variant: normal">I.11.</FONT> Delivery; Estimated Delivery Schedule; Delays</P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.11.1.</B></TD><TD STYLE="text-align: justify">The <I>Products</I> must be delivered according to DAP Incoterms 2020 at the <I>delivery site</I>
as indicated in the relevant <I>Vaccine Order Form</I>, it being noted, however, that each <I>participating Member State</I> shall
select one single place of delivery, within the EU territory, applicable to all deliveries to the said <I>participating Member
State</I> as per this <I>APA</I>. The <I>participating Member States</I> will be responsible for securing &ndash; and provide the
<I>contractor</I> with &ndash; any required import license to the <I>delivery site</I>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.11.2.</B></TD><TD STYLE="text-align: justify">Title to, and risk of loss of, the <I>Product</I> shall pass upon delivery in accordance with DAP
Incoterms 2020.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.11.3.</B></TD><TD STYLE="text-align: justify">The <I>Parties</I> acknowledge that the placing on the market, making available, distribution and
administration of the <I>Product</I> may require additional authorisations under local laws of the <I>participating Member State</I>.&nbsp;The
responsibility for compliance with local laws, including those regarding the handling, distribution and administration of the <I>Product</I>,
after the delivery at the relevant <I>delivery site</I> remains exclusively with the <I>participating Member States</I>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.11.4.</B></TD><TD STYLE="text-align: justify"><B>Estimated Delivery Schedule</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.85pt"></TD><TD STYLE="width: 20.15pt">(a)</TD><TD STYLE="text-align: justify">Subject to Article I.7.1, availability of the <I>Product</I> is subject to successful development
of the <I>Product</I>, the granting of the <I>EU marketing authorisation</I> and the successful manufacturing ramp up.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.85pt"></TD><TD STYLE="width: 20.15pt">(b)</TD><TD STYLE="text-align: justify">Subject to the above and subject to the <I>EU marketing authorisation</I> being granted by [*****], the estimated delivery schedule for the <I>Products</I> is as follows:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="margin-left: 1in; width: 80%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.4pt; border: Black 1pt solid; width: 51%; padding-right: 5.4pt; padding-bottom: 9pt; font-weight: normal; text-indent: 0in"><B>Estimated delivery periods</B></TD>
    <TD STYLE="padding-left: 5.4pt; width: 49%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 9pt; font-weight: normal; text-indent: 0in"><B>Volume (in millions of doses)</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 9pt; font-weight: normal; text-indent: 0in"><B>INITIAL EUROPEAN DOSES</B></TD>
    <TD STYLE="padding-left: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 9pt; font-weight: normal; text-indent: 0in"><B>225</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 9pt; font-weight: normal; text-indent: 0in">Q1 2021 </TD>
    <TD STYLE="padding-left: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 9pt; font-weight: normal; text-indent: 0in">[*****]</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 9pt; font-weight: normal; text-indent: 0in">Q2 2021</TD>
    <TD STYLE="padding-left: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 9pt; font-weight: normal; text-indent: 0in">[*****]</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 9pt; font-weight: normal; text-indent: 0in">Q3 2021</TD>
    <TD STYLE="padding-left: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 9pt; font-weight: normal; text-indent: 0in">[*****]</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 9pt; font-weight: normal; text-indent: 0in">Q4 2021</TD>
    <TD STYLE="padding-left: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 9pt; font-weight: normal; text-indent: 0in">[*****]</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 9pt; font-weight: normal; text-indent: 0in">Q1 2022</TD>
    <TD STYLE="padding-left: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 9pt; font-weight: normal; text-indent: 0in">[*****]</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="margin-left: 1in; width: 80%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.4pt; width: 51%; border: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 9pt; font-weight: normal; text-indent: 0in"><B>ADDITIONAL EUROPEAN DOSES</B></TD>
    <TD STYLE="padding-left: 5.4pt; width: 49%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 9pt; font-weight: normal; text-indent: 0in"><B>180</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 9pt; font-weight: normal; text-indent: 0in">Q2 2022</TD>
    <TD STYLE="padding-left: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 9pt; font-weight: normal; text-indent: 0in">[*****]</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 9pt; font-weight: normal; text-indent: 0in">Q3 2022</TD>
    <TD STYLE="padding-left: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 9pt; font-weight: normal; text-indent: 0in">[*****]</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 9pt; font-weight: normal; text-indent: 0in">Q4 2022</TD>
    <TD STYLE="padding-left: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 9pt; font-weight: normal; text-indent: 0in">[*****]</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.85pt"></TD><TD STYLE="width: 20.15pt">(c)</TD><TD STYLE="text-align: justify">The first delivery to a <I>participating Member State</I> shall take place at the latest by the
later of (i) the end of the estimated delivery periods as specified in Article I.11.4(b) above or (ii) the end of a period of [*****] calendar days after the <I>EU marketing authorisation </I>or the relevant <I>temporary national authorisation </I>(as the
case may be) is granted or (iii) the end of a period of [*****] calendar days after the <I>EU marketing authorisation</I>
in case the authorisation granted requires package labelling in deviation from the standardised generally acceptable packaging
as set out in Article I.13.1 below. Whilst the preceding sentence indicates the latest delivery dates for the first delivery, the
<I>Parties</I> agree that <I>doses</I> will be delivered if and when lots are released and not necessarily at the end of a quarter,
the [*****] period or the [*****] period (as the case may be).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-left: -5in; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-variant: normal">I.12.</FONT> Delays</P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.12.1.</B></TD><TD STYLE="text-align: justify">The <I>Parties</I> acknowledge that there is a risk that (i) the time-line for the <I>EU marketing
authorisation</I> or (ii) the time-line for scaling up the production of the <I>Product</I> may be delayed or that (iii) an <I>EU
marketing authorisation</I> may not be granted at all or (iv) the production of the <I>Product</I> may not be feasible.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.12.2.</B></TD><TD STYLE="text-align: justify">If there is a delay in the supply of the <I>Product</I> compared to the <I>estimated delivery schedule</I>,
the <I>contractor</I> will inform the <I>Commission</I> as soon as reasonably possible, explain the reasons for such delay and
submit a revised delivery schedule to the <I>Commission</I> which should be as close as possible to the <I>estimated delivery schedule</I>
while taking into account the reasons for the delay.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.12.3.</B></TD><TD STYLE="text-align: justify">The consequences if no <I>EU marketing authorisation</I> is granted or the production of the <I>Product</I>
is not feasible are exclusively dealt with in Article II.14.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-left: -4in; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-variant: normal">I.13.</FONT> Packaging; Labelling</P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.13.1.</B></TD><TD STYLE="text-align: justify">Unless and to the extent required otherwise under Union law or the laws of a <I>participating Member
State</I>, the <I>Product</I> supplied under this <I>APA</I> and/or under the <I>Vaccine Order Forms</I> shall be in a standardised
generally acceptable international packaging, including the package inserts and trade dress. For the sake of clarity, this means
that the <I>Product</I> packaging and/or inserts shall be in the English language or multilingual, but will not necessarily include
the specific languages of each of the <I>participating Member States</I>. To the extent that the <I>contractor</I> should be required
to modify the <I>Product</I> packaging (and/or package inserts) from the aforementioned planned packaging due to the regulatory
requirements in a certain <I>participating Member State</I>, the impact of such regulatory requirements on the timeline for availability
of the <I>Product</I> shall be taken into account in the Estimated Delivery Dates as set forth in Article&nbsp;I.11.4(c) above.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.13.2.</B></TD><TD STYLE="text-align: justify">The <I>contractor</I> shall comply with labelling requirements for the <I>Product</I> under Union
law and the respective laws of a <I>participating Member State</I> in all material respects, subject to any exceptions or procedural
relief that may be granted by a competent authority under such laws.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-left: -3in; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-variant: normal">I.14.</FONT> Warranties; Acceptance mechanism</P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.14.1.</B></TD><TD STYLE="text-align: justify">The <I>contractor</I> warrants to the <I>Commission</I> and the <I>participating Member States</I>
that</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.85pt"></TD><TD STYLE="width: 20.15pt">(a)</TD><TD STYLE="text-align: justify">as of the date hereof, this <I>APA</I> has been duly executed and is a legal, valid and binding
obligation on it, enforceable against it in accordance with its terms; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.85pt"></TD><TD STYLE="width: 20.15pt">(b)</TD><TD STYLE="text-align: justify">as of the date hereof, it is not under any obligation, contractual or otherwise, to any third party
in respect of the delivery of the <I>Initial European Doses</I> or that conflicts with or is inconsistent in any material respect
with the terms of this <I>APA</I> or that would impede the complete fulfillment of its obligations under this APA.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.14.2.</B></TD><TD STYLE="text-align: justify">The <I>contractor</I> warrants to the <I>Commission</I> and the <I>participating Member States</I>
that</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.85pt"></TD><TD STYLE="width: 20.15pt">(a)</TD><TD STYLE="text-align: justify">all <I>Products</I> supplied to the <I>participating Member States</I> shall at the time of delivery
comply with the <I>final specifications</I>;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -20.15pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>all <I>Products</I> supplied to the <I>participating Member States</I> shall at the time of delivery be free from any product
manufacturing defects; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -20.15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -20.15pt">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>at the time of delivery, it has good title to the <I>Products</I> delivered to the <I>participating Member States</I> pursuant
to this <I>APA</I> and it shall pass such title to the <I>participating Member States</I> free and clear of any security interests,
liens, or other encumbrances, including having obtained any necessary IP rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -20.15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.14.3.</B></TD><TD STYLE="text-align: justify">Given the current status of the clinical development program and in light of the extraordinary
circumstances of the execution and performance of this <I>APA</I>, the <I>contractor</I>, in particular, does not warrant that
the <I>Products</I> will show sufficient efficacy to prevent a <I>COVID-19</I> infection and/or be without inacceptable adverse
event symptoms beyond what will be documented in the ongoing and planned clinical trials or what will be documented in the leaflet
of the <I>Product</I>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.14.4.</B></TD><TD STYLE="text-align: justify">The <I>participating Member
                                         States</I>' [*****] remedy for a breach of a warranty set forth in Article&nbsp;I.14.2
                                         above and in respect of any circumstances relating to the status and condition of the
                                         <I>Product</I>, shall be, at the <I>contractor</I>'s election, (i) the issuance to the
                                         relevant <I>participating Member State</I> and/or to the <I>Commission</I> of a credit
                                         note (or refund) for the payments made in accordance with Articles I.17.1 and I.17.2
                                         with respect to the non-conforming <I>Product</I> or (ii) the supply of a replacement
                                         <I>Product </I>to the relevant <I>participating Member State</I> for the non-conforming
                                         <I>Product </I>in a timeframe (of [*****] calendar days at maximum) mutually agreed to by
                                         the <I>contractor </I>and the relevant <I>participating Member State</I>. [*****].</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.14.5.</B></TD><TD STYLE="text-align: justify">Upon delivery, the <I>participating Member States</I> shall immediately conduct a visual inspection
of (i) the pallet(s) or grouping boxes of the <I>Product </I>and (ii) the temperature monitoring device. The relevant <I>participating
Member State</I> shall conduct such visual inspection in a manner allowing it to complete the <I>Goods Received Form </I>properly
and promptly. The <I>Parties</I> agree that, if reasonably requested by the <I>contractor</I>, such inspection shall be conducted
in the presence of a representative and/or designee of the <I>contractor.</I></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.14.6.</B></TD><TD STYLE="text-align: justify">If an <I>apparent defect
                                         </I>is detected in the course of the visual inspection pursuant to Article&nbsp;I.14.5,
                                         the relevant <I>participating Member State </I>shall (i) document such <I>apparent&nbsp;defect
                                         </I>in the form of detailed comments in the relevant section of the <I>Goods Received
                                         Form</I> and (ii) provide comprehensive proof of the relevant issue in the form of photographs
                                         or other digital recordings together with the Goods Received Form. The <I>participating
                                         Member State</I> shall hand-over to the courier a copy of the <I>Goods Received Form
                                         </I>properly completed in accordance with Article&nbsp;I.14.5 and this Article&nbsp;I.14.6
                                         and, as the case may be, transmit (by email) the comprehensive proof of the <I>apparent
                                         defect</I> to the <I>contractor</I> as soon as possible and no later than [*****] calendar
                                         days after delivery.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.14.7.</B></TD><TD STYLE="text-align: justify">If the <I>Goods Received Form</I> does not document any <I>apparent defect</I> or if a <I>participating
Member State</I> fails to comply with Article I.14.5 and/or I.14.6, then the <I>Product</I> at stake shall be conclusively presumed
to be free of <I>apparent defects</I> and the <I>contractor</I> shall be authorised to send the corresponding invoice, this even
if the <I>participating Member State</I> did not issue formal proof of delivery. The <I>contractor</I> shall in that case have
[*****] to the <I>participating Member State</I> or the <I>Commission</I> in relation to such <I>Product</I>
with respect to <I>apparent defects</I>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.14.8.</B></TD><TD STYLE="text-align: justify">For any <I>hidden defect</I>, the <I>participating Member State</I> will be obligated to notify
the <I>contractor</I> in writing within [*****] calendar days following discovery of the said <I>hidden defect</I>. If <I>participating
Member State</I> fails to provide such notification within [*****] calendar days, the <I>participating Member State</I> ceases
its defect-related rights.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.14.9.</B></TD><TD STYLE="text-align: justify">The <I>participating Member States</I> shall observe and comply with such storage, handling, stock
control and operational requirements relating to <I>Product</I> as set forth in the <I>final specification</I> or otherwise required
by the <I>Product</I> labelling and applicable laws.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-left: 1.5in; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-variant: normal">I.15.</FONT> Product recalls</P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The <I>contractor </I>and the <I>participating
Member States </I>shall maintain at their own cost records necessary to permit a recall of any <I>Product</I> delivered to a <I>participating
Member State</I>. Each <I>Party</I> shall promptly notify the other <I>Parties</I> of any information, which might affect the
marketability, safety, or effectiveness of the <I>Product</I> or which might result in the recall or seizure of the <I>Product</I>
in a <I>participating Member State</I>. Upon receiving this notice or upon this discovery, each <I>Party</I> shall stop
making any further shipments, administration and/or use of any <I>product</I> in the relevant country in its possession or
control until a decision has been made whether a recall or some other corrective action is necessary. The <I>contractor</I>
is responsible for making any required notifications to EMA and/or any relevant national competent authority with respect to
a potential recall or abnormal restriction on supply. The decision to initiate a recall or to take some other corrective
action, if any, with respect to the product will be made by the <I>contractor</I> and/or the competent authority in
accordance with applicable laws. The [*****] shall implement such recall with respect to any <I>Product</I> delivered to
[*****] in close coordination with the [*****].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-left: 1.5in; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-variant: normal">I.16.</FONT> Price of the Product</P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.16.1.</B></TD><TD STYLE="text-align: justify">The <I>Product Price</I> (as defined in Article I.16.2 below applies to both the <I>Initial European
Doses</I> and the <I>Additional European Doses</I>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.16.2.</B></TD><TD STYLE="text-align: justify">The &quot;<B>Product Price</B>&quot; for the <I>Product</I> per <I>dose </I>shall be EUR [*****].</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.16.3.</B></TD><TD STYLE="text-align: justify">The <I>Product Price</I> (including, for the avoidance of doubt, the <I>up-front payments</I> on
the <I>Product Price</I> pursuant to Article I.17.1 below), is exclusive of sales, value-added and other taxes, as well as customs
and import fees and duties (sales, value-added and other taxes, as well as customs and import fees and duties together, the &quot;<B>ancillary
expenses</B>&quot;) to the <I>delivery site</I>. Such <I>ancillary expenses</I> will be charged in addition to the <I>Product Price
</I>if applicable and provided that no exemption for the respective <I>participating Member State</I> applies.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.16.4.</B></TD><TD STYLE="text-align: justify">The <I>participating Member States</I> will be responsible, at their own expenses and risks, for
any secondary distribution, storage and administration of the <I>Product</I>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-left: 1.5in; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-variant: normal">I.17.</FONT> Payment obligations</P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.17.1.</B></TD><TD STYLE="text-align: justify"><B>Up-front payment</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.85pt"></TD><TD STYLE="width: 20.15pt">(a)</TD><TD STYLE="text-align: justify">In order to de-risk the necessary investments of the <I>contractor</I> to increase the speed of
vaccine research and development and clinical trials and the preparation of the at-scale production capacity along the entire production
value chain in the EU required for a rapid deployment of the millions of <I>doses</I> of the <I>Product</I> according to the terms
of this <I>APA</I>, and in full understanding of the uncertainties associated with the aforementioned process, subject to <I>EU
marketing authorisation</I> or <I>temporary national authorisation </I>(as the case may be), the <I>Commission</I>, acting on behalf
and in the name of the <I>participating Member States</I>, and the <I>participating Member States</I> themselves shall contribute
to financing the relevant costs in the form of an up-front payment on the total <I>Product Price</I> of the <I>Initial European
Doses</I> (the &quot;<B>up-front payment</B>&quot;) as set forth in this Article I.17.1 as well as in the form of the <I>second
upfront payment</I> as set forth in Article I.17.2 and, as the case may arise, in the form of the <I>Additional Doses up-front
payment </I>as set forth in this Article I.17.2.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.85pt"></TD><TD STYLE="width: 20.15pt">(b)</TD><TD STYLE="text-align: justify">The <I>up-front payment</I> is EUR [*****] total (which will equal an up-front payment of EUR
[*****]).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.85pt"></TD><TD STYLE="width: 20.15pt">(c)</TD><TD STYLE="text-align: justify">Within [*****] calendar days following entry into force of the APA, the <I>contractor</I>
                                                                   shall send to the <I>Commission</I> a payment request for the payment of the <I>up-front payment</I> in accordance with
                                                                   Article II.15 below.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.85pt"></TD><TD STYLE="width: 20.15pt">(d)</TD><TD STYLE="text-align: justify">The <I>Commission</I>, acting on behalf and in the name of the <I>participating Member
                                                                   States</I>, shall pay the <I>up-front payment</I> within [*****] calendar days after receipt of a payment request from the <I>contractor</I>
                                                                   in accordance with Article I.17.1(c) above.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.17.2.</B></TD><TD STYLE="text-align: justify"><B>Payments under Vaccine Order Forms</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 51.85pt; text-align: justify">Pursuant to this Article I.17.2
and in accordance with their respective <I>Vaccine Order Forms</I>, the <I>participating Member States</I> shall make further payments
to the <I>contractor</I> as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 51.85pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.85pt"></TD><TD STYLE="width: 20.15pt">(a)</TD><TD STYLE="text-align: justify">With respect to the <I>Initial European Doses</I>, each <I>participating Member State</I>
                                                                   shall make a further up-front payment to the <I>contractor</I> in the amount of EUR [*****] for the volumes of the <I>Product</I>
                                                                   allocated to it pursuant to Articles I.8.1 and I.8.2 (the &quot;<B>second up-front payment</B>&quot;). The <I>second up-front
                                                                   payment</I> (plus value-added taxes, if any) shall be paid by the <I>participating Member State</I> within [*****] calendar
                                                                   days after <I>notification</I> by the <I>contractor</I> that the interim data package has been submitted to the EMA for the
                                                                   purpose of obtaining <I>EU marketing authorisation </I>for the <I>Product</I>, but no sooner than [*****] calendar days
                                                                   after receipt of a corresponding payment request from the <I>contractor</I> in accordance with Article II.15 below.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.85pt"></TD><TD STYLE="width: 20.15pt">(b)</TD><TD STYLE="text-align: justify">With respect to the <I>Additional European Doses</I>, and assuming that the <I>Commission</I> has
formally notified the <I>contractor</I> that a <I>participating Member State</I> wishes to acquire <I>Additional European Doses</I>
in accordance with Article I.8.3, each such <I>participating Member State</I> shall make an up-front payment to the <I>contractor</I>
in the amount of [*****]&nbsp;% of the Purchase Price per <I>dose </I>for the volumes of the <I>Product</I> allocated to it pursuant
to Article I.8.3 (the &quot;<B>Additional Doses up-front payment</B>&quot;). Such <I>Additional Doses up-front payment</I> (plus
value-added taxes, if any) shall be paid by the <I>participating Member State</I> within [*****] calendar days after conclusion
of the relevant <I>Vaccine Order Form</I> (or, if a participating Member State refuses to conclude the relevant <I>Vaccine Order
Form</I>, [*****] calendar days after the <I>contractor</I>'s explicit request to sign the relevant <I>Vaccine Order Form</I>),
but no sooner than [*****] calendar days after receipt of a corresponding payment request from the <I>contractor</I> in accordance
with Article II.15 below.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.85pt"></TD><TD STYLE="width: 20.15pt">(c)</TD><TD STYLE="text-align: justify">Each <I>participating Member State</I> shall pay the balance (plus <I>ancillary expenses </I>(as
defined in Article I.16.3) due on the <I>Product Price</I> for the volumes of the <I>Product</I> allocated to it pursuant to Articles
I.8.1 through I.8.3 within [*****] calendar days of each delivery (or offer to deliver if the <I>participating Member State</I>
illegitimately refuses acceptance of delivery), but no sooner than [*****] calendar days after receipt of a corresponding invoice
from the <I>contractor</I> in accordance with Article II.15 below. The balance due will be calculated on the basis of the relevant
<I>Product Price</I> of the delivered (or offered to deliver, as the case may be) <I>Products</I> as set out in Article I.16.1
above and under deduction of any <I>up-front payment</I>, <I>second up-front payment</I> and/or <I>Additional Doses up-front payment</I>
already received by the <I>contractor</I> for the relevant volumes of the <I>Product</I> delivered (or offered to deliver, as the
case may be).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.17.3.</B></TD><TD STYLE="text-align: justify"><B>Utilisation of the up-front payment and the second up-front payment</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 51.85pt; text-align: justify">The <I>contractor</I> intends
to use the <I>up-front payment</I> and the <I>second up-front payment</I> as further specified in Annex VII.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 51.85pt; text-align: justify">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-left: 1.5in; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-variant: normal">I.18.</FONT> Contractor's bank account</P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Payments must be made to the <I>contractor</I>&rsquo;s
bank account denominated in euro, identified as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 80%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; margin-left: 0.75in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 38%; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name of bank:</FONT></TD>
    <TD STYLE="width: 62%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[*****]</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Address of branch:</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[*****]</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Account holder:</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CureVac AG</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Account number: </FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        [*****]
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-left: 1.5in; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-variant: normal">I.19.</FONT> Communication details</P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the purpose of this <I>APA</I>, communications
must be made in English and sent to the following addresses:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If to the <I>Commission</I> to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt; text-align: justify">Directorate-General for Health
and Food Safety</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt; text-align: justify">E-mail: SANTE-PROCUREMENT@ec.europa.eu</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If to a <I>participating Member State</I>
to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt; text-align: justify">Cf. Annex I [*****]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If to the <I>contractor</I> to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt; text-align: justify">[*****]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt; text-align: justify">CUREVAC AG</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt; text-align: justify">Friedrich-Miescher-Str. 15,
72076 T&uuml;bingen, Deutschland</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt; text-align: justify">E-mail: [*****]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">By derogation from this Article, different
contact details for the <I>Commission</I>, the <I>participating Member States</I> or the <I>contractor</I> may be provided in <I>Vaccine
Order Forms</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-left: 1.5in; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-variant: normal">I.20.</FONT> Exploitation of the results of the APA</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.20.1.</B></TD><TD STYLE="text-align: justify">The <I>Parties</I> acknowledge and agree that the <I>contractor</I> shall be the sole owner of
all intellectual property rights generated during the development, manufacture, and supply of the <I>Product</I>, including all
know-how (collectively, the &ldquo;<B>Product IP Rights</B>&rdquo;). The <I>contractor</I> shall be entitled to exclusively exploit
any such <I>Product IP Rights</I>. Except as expressly set forth in this <I>APA</I>, the <I>contractor</I> does not grant to the
<I>Commission</I> and/or the <I>participating Member States</I> by implication, estoppel or otherwise, any right, title, licence
or interest in the <I>Product IP Rights</I>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.20.2.</B></TD><TD STYLE="text-align: justify">All rights not expressly granted by the <I>contractor</I> hereunder are reserved by the <I>contractor</I>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-left: 1.5in; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-variant: normal">I.21.</FONT> Applicable law and settlement of disputes</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1.5in; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.21.1.</B></TD><TD STYLE="text-align: justify">This <I>APA</I> shall be governed by the laws of Belgium.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.21.2.</B></TD><TD STYLE="text-align: justify"><B>Dispute Resolution</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.85pt"></TD><TD STYLE="width: 20.15pt">(a)</TD><TD STYLE="text-align: justify">In the event of a dispute between the <I>Parties</I> arising under or in connection with this <I>APA</I>
or the legal relationships established by this <I>APA</I>, the <I>Parties</I> shall first refer such dispute to informal dispute
resolution discussions between their respective representatives. Each of the <I>contractor</I> and the <I>Commission</I>, on behalf
of itself or on behalf of the <I>participating Member States</I> (as the case may be), may initiate such informal dispute resolution
by sending written notice of the dispute to the <I>contractor</I> or the <I>Commission</I> (as the case may be), and, within twenty
(20) calendar days of such notice, the representatives shall meet and attempt to resolve the dispute amicably by good faith negotiations.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.85pt"></TD><TD STYLE="width: 20.15pt">(b)</TD><TD STYLE="text-align: justify">If the <I>Parties</I> are not able to settle their dispute in accordance with lit. (a) above, the
<I>Commission</I>, the <I>participating Member States</I> and the <I>contractor</I> irrevocably submit to the exclusive jurisdiction
of the courts located in Brussels, Belgium to settle any dispute which may arise under or in connection with this <I>APA</I> or
the legal relationships established by this <I>APA</I>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-left: 1.5in; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-variant: normal">I.22.</FONT> Reporting</P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.22.1.</B></TD><TD STYLE="text-align: justify">The <I>contractor</I> will provide to the <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Commission</I></FONT>,
at the <FONT STYLE="font-family: Times New Roman, Times, Serif">latter&rsquo;s </FONT>request until full <I>EU marketing authorisation</I>
for the <I>Product</I> has been granted, the following physical or electronic data:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 63.35pt"></TD><TD STYLE="width: 28.8pt">(i)</TD><TD STYLE="text-align: justify">updates on progress made in terms of clinical development of the <I>Product</I>; included interim
and final results of clinical studies of the <I>Product</I>;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 63.35pt"></TD><TD STYLE="width: 28.8pt">(ii)</TD><TD STYLE="text-align: justify">progress on the build-up of manufacturing capacities;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 63.35pt"></TD><TD STYLE="width: 28.8pt">(iii)</TD><TD STYLE="text-align: justify">updates on progress, challenges and opportunities on establishment of the supply chain; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 63.35pt"></TD><TD STYLE="width: 28.8pt">(iv)</TD><TD STYLE="text-align: justify">the use of the upfront payments by the Commission and the <I>participating Member States,</I> linked
to points (i) to (iii), in general terms;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 51.85pt; text-align: justify">it being understood that the
information pursuant to points (i) through (iii) above shall not [*****].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 51.85pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.22.2.</B></TD><TD STYLE="text-align: justify">In addition, the <I>contractor</I> shall keep the <I>Commission</I> and the <I>participating Member
States</I> informed about any signal detected during the pharmacovigilance or vaccine monitoring programs in relation to the <I>Product</I>
within five (5) working days from notifying the EMA.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-left: 1.5in; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-variant: normal">I.23.</FONT> Indemnification</P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.23.1.</B></TD><TD STYLE="text-align: justify">The <I>Commission</I>, on behalf of the <I>participating Member States</I>, declares that the use
of the <I>Products</I> delivered under this <I>APA</I> and/or the <I>Vaccine Order Forms</I> will happen under epidemic conditions
requiring such use, and that the administration of the <I>Products</I> will therefore be conducted under the sole responsibility
of the <I>participating Member States</I>.&nbsp;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.23.2.</B></TD><TD STYLE="text-align: justify">The <I>Parties</I> further declare that the provisions contained in this indemnification clause,
including the exceptions to the indemnification undertakings, reflect the exceptional circumstances of the <I>COVID-19 pandemic</I>
and the need to develop new vaccines at an unprecedented speed in order to allow for very large scale immunisation.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.23.3.</B></TD><TD STYLE="text-align: justify">On this basis, each <I>participating Member State</I> shall indemnify and hold harmless the <I>contractor</I>,
its Affiliates, sub-contractors and sub-licensees, including contract partners involved in the research, development (including
pre-clinical and clinical testing), manufacturing and/or delivery; and officers, directors, employees and other agents, representatives
and service providers of each (together, the &ldquo;<B>Indemnified Persons</B>&rdquo;) for liability incurred and normally borne
by them relating to harm, damages and losses (together, the &quot;<B>Losses</B>&quot;) as further specified in Article I.23.5 arising
from the use and deployment of the <I>Products</I> supplied to the <I>participating Member State</I> (or another entity appointed
by that <I>participating Member State</I>) under this <I>APA</I>, irrespective of the time when the <I>Losses</I> occur.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.23.4.</B></TD><TD STYLE="text-align: justify">Such indemnification will not be available to the <I>Indemnified Persons</I> to the extent that
[*****].</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.23.5.</B></TD><TD STYLE="text-align: justify">Indemnification pursuant to Article I.23.3 will only be available for <I>Losses</I> that consist
of: (i) liability towards the injured <I>Party</I> [*****] for death, physical, mental or
emotional injury, illness, disability, cost of care, property loss or damage, loss of earnings, and business interruption; and
(ii) all reasonable and necessary costs related to such Losses including legal fees, expert fees and other litigation or settlement
expenses.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.23.6.</B></TD><TD STYLE="text-align: justify">[*****].</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.23.7.</B></TD><TD STYLE="text-align: justify">In case liability has been incurred by the <I>Indemnified Persons</I> for <I>Losses</I>, the <I>contractor</I>
shall give the <I>participating Member State</I> in question, or an independent expert as referred to in Article I.23.8, access
to all information reasonably necessary for the <I>participating Member State</I> to indemnify the <I>Indemnified Persons</I> and
to verify whether the above mentioned conditions are fulfilled.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.23.8.</B></TD><TD STYLE="text-align: justify">The <I>participating Member State</I> shall be allowed to access the information through an independent
expert in the field of damage claims, in particular in the field of public health, subject to an obligation of strict confidentiality.
In that case, the <I>participating Member State</I> shall notify the <I>contractor</I> in advance of its intention to use an expert
and the identity of such expert. The <I>contractor</I> shall be allowed to object to the use of an expert within 30 days counted
from such notification, if it puts forward reasonable grounds on the basis of which the specific expert in question should not
be permitted access to such information, such as <I>conflict of interest</I>. In such case, the <I>participating Member State</I>
shall be allowed to appoint a new independent expert and notify that expert to the <I>contractor</I>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.23.9.</B></TD><TD STYLE="text-align: justify">The <I>contractor</I> shall promptly inform the relevant <I>participating Member State</I> of any
damage claims brought against any of the <I>Indemnified Persons</I> (a &ldquo;<B>Third Party Claim</B>&rdquo;), stating the nature
and basis of the damage claim in question and, if possible, the estimated amount of damages. The <I>contractor</I> shall use reasonable
efforts to keep the <I>participating Member State</I> informed of any developments relating to such <I>Third Party Claim</I>, including
updates on the estimated amount of damages.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.23.10.</B></TD><TD STYLE="text-align: justify">The <I>contractor</I> shall ensure that the <I>Indemnified Persons</I> take such commercially reasonable
actions to avoid, defend or settle the <I>Third Party Claim</I> and to mitigate the liability incurred. Within [*****] calendar
days of the submission by the <I>contractor</I> of an invoice for such actually incurred Losses (also when they arise during the
course of legal proceedings or settlement discussions), the <I>participating Member State</I> shall provide written confirmation
to the <I>contractor</I> that it will indemnify such losses, subject to the conditions set out in the present indemnification clause,
in particular the conditions set above. [*****]. The <I>contractor</I> shall
keep the <I>participating Member State</I> reasonably informed in relation to the <I>Third Party Claim</I> and the <I>contractor</I>
may settle the <I>Third Party Claim</I> only with the prior consent of the <I>participating Member State</I> (such consent not
to be unreasonably conditioned, withheld or delayed).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.23.11.</B></TD><TD STYLE="text-align: justify">Alternatively, the <I>contractor</I> may request, to the extent possible under the applicable rules
of procedure, the <I>participating Member State</I> to assume (with its own counsel and at its own costs) sole control of the defence
or settlement of the <I>Third Party Claim</I>; provided that: (i) the <I>participating Member State</I> shall reasonably take the
<I>contractor</I>'s interests into consideration and shall not settle such <I>Third Party Claim</I> without the prior written consent
of the <I>contractor</I> (such consent not to be unreasonably conditioned, withheld or delayed); and (ii) the <I>contractor</I>
shall have the right, but not the obligation, to participate in the defence or settlement of the <I>Third
Party Claim</I> and to retain its own counsel in connection with such <I>Third Party Claim</I> at its own expense. [*****].</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.23.12.</B></TD><TD STYLE="text-align: justify">These provisions apply until a final determination by the competent courts of a ground for exception
to the indemnification, as stipulated in Articles I.23.4. Any claims of <I>contractor</I> under this Article I.23 shall be time
barred not earlier than [*****] after the final expiration of all relevant statutes of limitation periods for the relevant
<I>Third Party Claim</I>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>I.23.13.</B></TD><TD STYLE="text-align: justify">The <I>Parties</I> acknowledge and agree that the provisions of this indemnification clause are
reasonable and necessary to protect the legitimate interest of the <I>Indemnified Persons</I>. However, if any provision in this
clause were to be held to be illegal, invalid or unenforceable, in whole or in part, then such provision shall not be nullified
but the <I>Parties</I>, including the <I>participating Member State</I>s, shall be deemed to have agreed to such provision that
conforms with the limitations imposed by applicable law and that is as close as possible to the original intention of the <I>Parties</I>
and has the same or as similar as possible economic effect, and such provision shall be automatically reformed accordingly. <B><BR STYLE="clear: both">
</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="font-variant: normal">II.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>GENERAL CONDITIONS</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-left: 1.5in; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-variant: normal">II.1.</FONT> Severability</P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.2pt 0pt 0; text-align: justify">Each provision of this <I>APA</I>
is severable and distinct from the others. If a provision is or becomes illegal, invalid or unenforceable to any extent, it must
be severed from the remainder of the <I>APA</I>. This does not affect the legality, validity or enforceability of any other provisions
of the <I>APA</I>, which continue in full force and effect. The illegal, invalid or unenforceable provision must be replaced by
a legal, valid and enforceable substitute provision which corresponds as closely as possible with the actual intent of the <I>Parties</I>
under the illegal, invalid or unenforceable provision. The <I>APA</I> must be interpreted as if it had contained the substitute
provision as from its entry into force.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.2pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-left: 1.5in; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-variant: normal">II.2.</FONT> Provision of Supplies</P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.2.1.</B></TD><TD STYLE="text-align: justify">The <I>contractor</I> must provide supplies that are at the time of delivery free from any <I>Product
Manufacturing Defects</I>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.2.2.</B></TD><TD STYLE="text-align: justify">All periods specified in the <I>APA</I> are calculated in calendar days, unless otherwise specified.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.2.3.</B></TD><TD STYLE="text-align: justify">The <I>contractor</I> must immediately <I>notify</I> the <I>Commission</I> of any changes in the
exclusion situations as declared, according to Article 137 (1) of Regulation (EU) 2018/1046.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-left: 1.5in; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-variant: normal">II.3.</FONT> Communication between the parties</P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.3.1.</B></TD><TD STYLE="text-align: justify"><B>Form and means of communication</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any communication of information, notices
or documents under the <I>APA</I> must:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.85pt"></TD><TD STYLE="width: 20.15pt">(a)</TD><TD>be made in writing in paper or electronic format in the language of the contract;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.85pt"></TD><TD STYLE="width: 20.15pt">(b)</TD><TD>bear the <I>APA</I> number and, if applicable, the <I>Vaccine Order Form</I> number;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.85pt"></TD><TD STYLE="width: 20.15pt">(c)</TD><TD>be made using the relevant communication details set out in Article I.8; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.85pt"></TD><TD STYLE="width: 20.15pt">(d)</TD><TD>be sent by mail or e-mail.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a <I>Party</I> requests written confirmation
of an e-mail within a reasonable time, the other <I>Party</I> must provide an original signed paper version of the communication
as soon as possible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The <I>Parties</I> agree that any communication
made by e-mail has full legal effect and is admissible as evidence in judicial proceedings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.3.2.</B></TD><TD STYLE="text-align: justify"><B>Date of communications by mail and e-mail</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any communication is deemed to have been
made when the receiving <I>Party</I> receives it, unless this <I>APA</I> contract refers to the date when the communication was
sent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">E-mail is deemed to have been received
by the receiving <I>Party</I> on the day of dispatch of that e-mail, provided that it is sent to the e-mail address indicated below.
The sending <I>Party</I> must be able to prove the date of dispatch. In the event that the sending <I>Party</I> receives a non-
delivery report, it must make every effort to ensure that the other <I>Party</I> actually receives the communication by e-mail
or mail. In such a case, the sending <I>Party</I> is not held in breach of its obligation to send such communication within a specified
deadline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mail sent to the <I>Commission</I> or the
<I>participating Member State</I> is deemed to have been received on the date on which the department responsible referred to below
registers it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Formal notifications </I>are considered
to have been received by the receiving <I>Party</I> on the date of receipt indicated in the proof received by the sending <I>Party</I>
that the message was delivered to the specified recipient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-left: 1.5in; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-variant: normal">II.4.</FONT> Liability</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.4.1.</B></TD><TD STYLE="text-align: justify">[*****], the <I>Commission</I> and the <I>participating Member State</I>s
are not liable for any damage or loss caused by the <I>contractor</I>, including any damage or loss to third parties occurred during
or as a consequence of the performance of the <I>APA</I> or any <I>Vaccine Order Forms</I>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.4.2.</B></TD><TD STYLE="text-align: justify">If required by the relevant applicable legislation, the <I>contractor</I> must take out an insurance
policy against risks and damage or loss relating to the performance of the <I>APA</I> or any <I>Vaccine Order Forms</I>. Upon request,
the <I>contractor</I> must provide evidence of insurance coverage to the <I>Commission</I>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.4.3.</B></TD><TD STYLE="text-align: justify">If a third party brings any action against the <I>Commission</I> or the <I>participating Member
State</I> in connection with the performance of the <I>APA</I> or any <I>Vaccine Order Forms</I>, including any action for alleged
breach of intellectual property rights, the <I>contractor</I> must provide reasonable assistance to the <I>Commission</I> or the
<I>participating Member State</I>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-left: 1.5in; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-variant: normal">II.5.</FONT> Conflict of interest and professional conflicting interests</P>



<P STYLE="margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.5.1.</B></TD><TD STYLE="text-align: justify">The <I>contractor</I> must take all the necessary measures to prevent any situation of <I>conflict
of interest</I> or <I>professional conflicting interest</I>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.5.2.</B></TD><TD STYLE="text-align: justify">The <I>contractor</I> must notify the <I>Commission</I> in writing as soon as possible of any situation
that could constitute a <I>conflict of interest</I> or a <I>professional conflicting interest</I> during the performance of the
<I>APA</I>. The <I>contractor</I> must immediately take action to rectify the situation.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 51.85pt; text-align: justify">The <I>Commission</I> may do
any of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 51.85pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.85pt"></TD><TD STYLE="width: 20.15pt">(a)</TD><TD>verify that the <I>contractor</I>&rsquo;s action is appropriate;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.85pt"></TD><TD STYLE="width: 20.15pt">(b)</TD><TD>require the <I>contractor</I> to take further action within a specified deadline;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.85pt"></TD><TD STYLE="width: 20.15pt">(c)</TD><TD>decide, on behalf of the <I>participating Member States</I>, not to award a <I>Vaccine Order Form</I> to the <I>contractor</I>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.5.3.</B></TD><TD STYLE="text-align: justify">The <I>contractor</I> must pass on all the relevant obligations in writing to:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.85pt"></TD><TD STYLE="width: 20.15pt">(a)</TD><TD>its personnel;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.85pt"></TD><TD STYLE="width: 20.15pt">(b)</TD><TD>any natural person with the power to represent it or take decisions on its behalf;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.85pt"></TD><TD STYLE="width: 20.15pt">(c)</TD><TD>third parties involved in the performance of the <I>APA</I>, including subcontractors.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 51.85pt; text-align: justify">The <I>contractor</I> must
also ensure that the persons referred to above are not placed in a situation which could give rise to conflicts of interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 51.85pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 51.85pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 51.85pt; text-align: justify">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-left: 1.5in; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-variant: normal">II.6.</FONT> Confidentiality and public announcements</P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.6.1.</B></TD><TD STYLE="text-align: justify">The <I>Commission</I>, the <I>participating Member States</I> and the <I>contractor</I> must treat
with strict confidentiality any <I>confidential information or documents</I> in connection with the APA.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.6.2.</B></TD><TD STYLE="text-align: justify">The <I>Commission</I>, the <I>participating Member States</I> and the <I>contractor</I> shall:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.85pt"></TD><TD STYLE="width: 20.15pt">(a)</TD><TD STYLE="text-align: justify">not use <I>confidential information or documents </I>for any purpose other than to perform their
respective obligations under the <I>APA</I> or a <I>Vaccine Order Form</I> without the prior written agreement of the disclosing
<I>Party</I>;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.85pt"></TD><TD STYLE="width: 20.15pt">(b)</TD><TD STYLE="text-align: justify">ensure the protection of such <I>Confidential information or documents </I>with the same level
of protection as their own <I>confidential information or documents </I>and in any case with due diligence;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.85pt"></TD><TD STYLE="width: 20.15pt">(c)</TD><TD STYLE="text-align: justify">not disclose, directly or indirectly, <I>confidential information or documents </I>to third parties
without the prior written agreement of the other <I>Party</I>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.6.3.</B></TD><TD STYLE="text-align: justify">Notwithstanding the above, the Parties may disclose <I>confidential information or documents </I>to
their directors, officers and employees and, in the case of the <I>contractor</I>, to its subcontractors and their directors, officers
and employees as well as to those of any corporation directly or indirectly controlling, controlled by, or under common control
with the <I>contractor</I> (control being the ownership of more than fifty percent (50 %) of the outstanding voting stock of a
corporation), and/or any company, individual or organisation retained by them to assist in the <I>implementation of the APA</I>,
provided that each such company, individual and organisation must be legally bound to comply with this Article.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.6.4.</B></TD><TD STYLE="text-align: justify">The confidentiality obligations set out in this Article are binding on the <I>Commission</I>, the
<I>participating Member State</I> and the <I>contractor</I> during the performance of the <I>APA</I> and for as long as the information
or documents remain confidential unless:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.85pt"></TD><TD STYLE="width: 20.15pt">(a)</TD><TD>the disclosing <I>Party</I> agrees to release the receiving <I>Party</I> from the confidentiality obligation earlier;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.85pt"></TD><TD STYLE="width: 20.15pt">(b)</TD><TD>the <I>confidential information or documents </I>become public through other means than a breach of the confidentiality obligation;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.85pt"></TD><TD STYLE="width: 20.15pt">(c)</TD><TD>the applicable law requires the disclosure of the <I>confidential information or documents</I>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.6.5.</B></TD><TD STYLE="text-align: justify">The <I>contractor</I> must obtain from any natural person with the power to represent it or take
decisions on its behalf, as well as from third parties involved in the performance of the <I>APA</I> a commitment that they will
comply with this Article. At the request of the <I>Commission</I>, the <I>contractor</I> must provide a document providing evidence
of this commitment.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.6.6.</B></TD><TD STYLE="text-align: justify">The <I>contractor</I> acknowledges that the <I>Commission</I> is subject to requirements laid down
under Regulation (EC) 1049/2001. The <I>Commission</I> commits that it will consult with the <I>contractor</I> on any disclosure
request concerning <FONT>documents containing <I>confidential information</I></FONT> as provided for in
Article 4(4) of said Regulation.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.6.7.</B></TD><TD STYLE="text-align: justify">Notwithstanding the above, each <I>Party</I> may issue a press release and/or other public statement
disclosing the total contract volume and value of the <I>APA</I> and/or the <I>Vaccine Order Form</I>. The Parties shall consult
together on the timing, contents and manner of any press release relating to this <I>APA</I>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-left: 1.5in; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-variant: normal">II.7.</FONT> Processing of personal data</P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.7.1.</B></TD><TD STYLE="text-align: justify"><B>Processing of personal data by the <I>Commission</I></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any personal data included in or relating
to the <I>APA</I>, including its implementation, shall be processed in accordance with Regulation (EU) 2018/1725. Such data shall
be processed solely for the purposes of the implementation, management and monitoring of the <I>APA</I> by the data controller.
For the purpose of this provision, the data controller for the <I>Commission</I> shall be the Director-General of the European
<I>Commission</I>'s Directorate-General for Health and Food Safety. The data protection notice is available at <U>https://ec.europa.eu/info/data-protection-
public-procurement-procedures_en.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The <I>contractor</I> or any other person
whose personal data is processed by the data controller in relation to this <I>APA</I> has specific rights as a data subject under
Chapter III (Articles 14-25) of Regulation (EU) 2018/1725, in particular the right to access, rectify or erase their personal data
and the right to restrict or, where applicable, the right to object to processing or the right to data portability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Should the <I>contractor</I> or any other
person whose personal data is processed in relation to this <I>APA</I> have any queries concerning the processing of its personal
data, it shall address itself to the data controller. They may also address themselves to the Data Protection Officer of the data
controller. They have the right to lodge a complaint at any time to the European Data Protection Supervisor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.7.2.</B></TD><TD STYLE="text-align: justify"><B>Processing of personal data by the contractor</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The processing of personal data by the
<I>contractor</I> shall meet the requirements of Regulation (EU) 2018/1725 and be processed solely for the purposes set out by
the controller.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-left: 1.5in; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-variant: normal">II.8.</FONT> Subcontracting</P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.8.1.</B></TD><TD STYLE="text-align: justify">The <I>contractor</I> may not subcontract and have the <I>APA</I> (including <I>Vaccine Order Forms</I>
entered into under the <I>APA</I>) implemented by third parties without prior written authorisation of the <I>Commission</I>, it
being noted that the <I>Commission</I> will not unreasonably withhold or delay such authorisation. The manufacturing network partners
and their manufacturing sites as identified in Annex V are deemed pre-approved for the purpose of the foregoing sentence.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.8.2.</B></TD><TD STYLE="text-align: justify">In the case of subcontracting, the <I>contractor</I> remains bound by its contractual obligations
and is solely responsible for the performance of the <I>APA</I>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.8.3.</B></TD><TD STYLE="text-align: justify">The <I>contractor</I> must ensure that the subcontract does not affect the rights of the <I>Commission</I>
and the <I>participating Member State</I>s under this <I>APA</I>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.8.4.</B></TD><TD STYLE="text-align: justify">The <I>Commission</I> may request the <I>contractor</I> to replace a subcontractor found to be
in a situation provided for in Article II.14.2(d) and (e).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-left: 1.5in; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-variant: normal">II.9.</FONT> Amendments</P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.9.1.</B></TD><TD STYLE="text-align: justify">Any amendment to the <I>APA</I> must be made in writing by the <I>contractor</I> and the <I>Commission</I>,
(also) acting in the name and on behalf of all <I>participating Member States</I>, and any amendment to a <I>Vaccine Order Form</I>
must be made in writing by the <I>contractor</I> and the relevant <I>participating Member State</I>. The conclusion of a <I>Vaccine
Order Form</I> does not constitute an amendment to the <I>APA</I>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.9.2.</B></TD><TD STYLE="text-align: justify">No amendment can make changes to the <I>APA</I> or a <I>Vaccine Order Form</I> that might alter
the initial conditions of the procurement procedure or result in unequal treatment of tenderers or contractors.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-left: 1.5in; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-variant: normal">II.10.</FONT> Assignment</P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.10.1.</B></TD><TD STYLE="text-align: justify">The <I>contractor</I> cannot assign any of the obligations arising from the <I>APA</I>, without
prior written authorisation from the <I>Commission</I>. In such cases, the <I>contractor</I> must provide the <I>Commission</I>
with the identity of the intended assignee.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.10.2.</B></TD><TD STYLE="text-align: justify">Any obligation assigned by the <I>contractor</I> without authorisation is not enforceable against
the <I>Commission</I>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-left: 1.5in; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-variant: normal">II.11.</FONT> Force majeure</P>



<P STYLE="margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.11.1.</B></TD><TD STYLE="text-align: justify">If the <I>contractor</I>, or one of its subcontractors, is affected by <I>force majeure</I>, the
<I>contractor</I> must immediately <I>notify </I>the <I>Commission</I> or, if only the performance of certain <I>Vaccine Order
Forms</I> are affected, the relevant <I>participating Member State(s)</I>, stating the nature of the circumstances, their likely
duration and foreseeable effects. If the <I>Commission</I> and/or a <I>participating Member State</I> is affected by <I>force majeure</I>,
the <I>Commission </I>and/or the relevant <I>participating Member State(s)</I> must immediately <I>notify </I>the <I>contractor</I>,
stating the nature of the circumstances, their likely duration and foreseeable effects.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.11.2.</B></TD><TD STYLE="text-align: justify">A <I>Party</I> is not liable for any delay or failure to perform its obligations under the <I>APA</I>
if that delay or failure results from a <I>force majeure</I>. As long as the <I>contractor</I> is unable to fulfil its contractual
obligations owing to <I>force majeure</I>, it has the right to remuneration only for the <I>doses</I> of the <I>Product</I> actually
delivered.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.11.3.</B></TD><TD STYLE="text-align: justify">The <I>Parties</I> must take all necessary measures to limit any damage due to <I>force majeure</I>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-left: 1.5in; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-variant: normal">II.12.</FONT> Reduction in price</P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.12.1.</B></TD><TD STYLE="text-align: justify"><B>Quality standards</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the <I>contractor</I> fails to deliver
the <I>Product</I> in accordance with the <I>APA</I>, the <I>participating Member State</I> in question may reduce or recover payments
in accordance with Article I.14.4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.12.2.</B></TD><TD STYLE="text-align: justify"><B>Procedure</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The <I>participating Member State</I> in
question must <I>formally notify </I>the <I>contractor</I> of its intention to reduce payment and the corresponding calculated
amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The <I>contractor</I> has 30 days following
the date of receipt to submit observations. Failing that, the decision becomes enforceable the day after the time limit for submitting
observations has elapsed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the <I>contractor</I> submits observations,
the <I>participating Member State</I> in question, taking into account the relevant observations, must <I>notify </I>the <I>contractor</I>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.85pt"></TD><TD STYLE="width: 20.15pt">(a)</TD><TD>of the withdrawal of its intention to reduce payment; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.85pt"></TD><TD STYLE="width: 20.15pt">(b)</TD><TD>of its final decision to reduce payment and the corresponding amount.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Split-Segment; Name: a2 -->
<P STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 141.75pt"></TD><TD STYLE="width: 32.4pt"><FONT STYLE="font-variant: normal">II.13.</FONT></TD><TD>Suspension of the APA</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.13.1.</B></TD><TD STYLE="text-align: justify"><B>Suspension by the contractor</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If and to the extent the <I>contractor</I>,
including any of its subcontractors, is affected by <I>force majeure</I>, it may suspend the performance of the <I>APA</I> and/or
the <I>Vaccine Order Forms</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the performance of the <I>APA</I> or
both the performance of the <I>APA</I> and the performance of all <I>Vaccine Order Forms</I> are affected, the <I>contractor</I>
must immediately <I>notify </I>the <I>Commission</I> of the suspension or, if only the performance of certain <I>Vaccine Order
Forms</I> is affected, the <I>contractor</I> must immediately <I>notify </I>the relevant <I>participating Member State(s)</I> of
the suspension. The <I>notification </I>must include a description of the <I>force majeure </I>and state when the <I>contractor</I>
expects to resume the performance of the <I>APA</I> and/or the <I>Vaccine Order Forms</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The <I>contractor</I> must <I>notify </I>the
<I>Commission</I> or the relevant <I>participating Member State(s)</I> (as the case may be) as soon as it is able to resume performance
of the <I>APA </I>and/or <I>Vaccine Order Form</I>, unless the <I>APA</I> or the <I>Vaccine Order Form</I> has already been terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.13.2.</B></TD><TD STYLE="text-align: justify"><B>Suspension by the <I>Commission</I> or the <I>Participating Member State</I></B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The <I>Commission</I> or the <I>participating
Member State</I> with respect to its <I>Vaccine Order Form</I> may suspend the performance of the <I>APA</I> or performance of
a <I>Vaccine Order Form</I>, respectively, or any part of it:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.85pt"></TD><TD STYLE="width: 20.15pt">(a)</TD><TD>if the procedure for awarding the <I>APA</I> or a <I>Vaccine Order Form</I> or the performance of the <I>APA</I> proves to
have been subject to <I>irregularities</I> or <I>fraud</I> on the part of the <I>contractor</I>;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.85pt"></TD><TD STYLE="width: 20.15pt">(b)</TD><TD>in order to verify whether the presumed <I>irregularities</I> or <I>fraud</I> on the part of the <I>contractor</I> have actually
occurred.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The <I>Commission</I> or the <I>participating
Member State</I> in question must <I>formally notify </I>the <I>contractor</I> of the suspension and the reasons for it. Suspension
takes effect on the date of <I>formal notification</I>, or at a later date if the <I>formal notification </I>so provides.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The <I>Commission</I> or the <I>participating
Member State</I> in question must <I>notify </I>the <I>contractor</I> as soon as the verification is completed whether:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.85pt"></TD><TD STYLE="width: 20.15pt">(a)</TD><TD>it is lifting the suspension; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.85pt"></TD><TD STYLE="width: 20.15pt">(b)</TD><TD>it intends to terminate the <I>APA</I> or a <I>Vaccine Order Form</I> under Article II.14.2 e).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The <I>contractor</I> is entitled to compensation
for suspension of any part of the <I>APA</I> or a <I>Vaccine Order Form</I> if the verification comes to the result that the presumed
<I>irregularities</I> or <I>fraud</I> on the part of the <I>contractor</I> did not occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The <I>Commission</I> may in addition suspend
the time allowed for payments in accordance with Article&nbsp;II.16.4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 141.75pt"></TD><TD STYLE="width: 32.4pt"><FONT STYLE="font-variant: normal">II.14.</FONT></TD><TD>Termination of the APA</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.14.1.</B></TD><TD STYLE="text-align: justify"><B>Grounds for automatic termination of the APA</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The APA will be automatically
terminated if and when the <I>contractor</I> notifies the <I>Commission</I> of its inability to provide the <I>Product </I>because
of, and only because of, the following reasons: (i) the clinical trial results not being satisfactory, (ii) the clinical
trial results not meeting their end point in terms of efficacy or safety or (iii) the <I>EU marketing authorisation</I> not
being granted. The <I>notification</I> of the <I>contractor</I> shall set out in detail the underlying reasons for automatic
termination of the <I>APA</I>. The termination will be effective unless the <I>Commission</I> objects in writing within
thirty (30) calendar days following the notification by the <I>contractor</I>, such objection may only be issued based on
reasonable grounds given the evidence of one the three reasons (points (i) through (iii)) stated above and taking into
account the severity of the impact that the continuation of the <I>APA</I> would have on the <I>contractor</I>'s business. If
and once the termination becomes effective the <I>contractor </I>may not sell and/or deliver the <I>Product</I> to any third
party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.14.2.</B></TD><TD STYLE="text-align: justify"><B>Grounds for termination by the Commission or the participating Member States</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The <I>Commission</I>, acting on behalf
and in the name of the <I>participating Member States</I>, may terminate the <I>APA</I> in the following circumstances (a) through
(h), and the <I>participating Member State</I>s may terminate their respective <I>Vaccine Order Forms</I> in the following circumstances
(b) through (h). Except for the termination right in case of (a) below, a right of termination only exists if the reason giving
rise of the right to terminate is not cured, removed or otherwise no longer existent within [*****] calendar days of receipt
by the <I>contractor</I> of <I>formal notification</I> from the <I>Commission</I> of the intention to terminate the APA or <I>participating
Member States</I> to terminate the respective <I>Vaccine Order Forms</I>, which <I>formal notification</I> shall include a reasonably
detailed description of the alleged breach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.25pt"></TD><TD STYLE="width: 21.25pt">(a)</TD><TD STYLE="text-align: justify">If no <I>EU marketing authorisation</I> is granted by [*****], or any other day mutually
agreed upon by the <I>Commission</I> and the <I>contractor</I> in writing or if by that date no <I>doses</I> of the <I>Initial
European Doses</I> have been supplied to any of the <I>participating Member States</I>. If the <I>contractor</I> expects that such
a situation may occur, it will inform the <I>Commission</I> well in advance of such possibility, explain the reasons behind such
delays and, if possible, propose a remedy for the situation, including a revised delivery schedule.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.25pt"></TD><TD STYLE="width: 21.25pt">(b)</TD><TD STYLE="text-align: justify">If the <I>contractor</I> is in material <I>breach of obligations</I> (i) in relation to the main
performance obligations such as the obligations under the [*****], (ii) in relation
to the obligations under [*****] or (iii), in the case of a <I>participating
Member State</I>, in relation to the obligations under a <I>Vaccine Order Form</I>, or if the <I>contractor</I> [*****] refuses
to sign one or several <I>Vaccine Order Form(s)</I>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.25pt"></TD><TD STYLE="width: 21.25pt">(c)</TD><TD STYLE="text-align: justify">If the <I>contractor</I> is in one of the situations provided for in points (a) and (b) of Article
136(1) of the Financial Regulation<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>4</SUP></FONT>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.25pt"></TD><TD STYLE="width: 21.25pt">(d)</TD><TD STYLE="text-align: justify">If the <I>contractor</I>, any of the members of its management board or any of its key employees
involved in the performance of this <I>APA</I> is in one of the situations provided for in points (c) to (h) of Article 136(1)
or to Article 136(2) of the Financial Regulation.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.25pt"></TD><TD STYLE="width: 21.25pt">(e)</TD><TD STYLE="text-align: justify">If the procedure for awarding the <I>APA</I> or the performance of the <I>APA</I> prove to have
been subject to <I>irregularities</I> or <I>fraud </I>on the part of the <I>contractor</I>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.25pt"></TD><TD STYLE="width: 21.25pt">(f)</TD><TD STYLE="text-align: justify">If the <I>contractor</I> is in a situation that constitutes a <I>conflict of interest </I>or a
<I>professional conflicting interest </I>and such situation is not resolved by the <I>contractor</I> in accordance with Article
II.5.2.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><SUP>4
</SUP></FONT>Regulation (EU, Euratom) 2018/1046 of the European Parliament and of the Council of 18 July 2018 on the financial
rules applicable to the general budget of the Union, amending Regulations (EU) No 1296/2013, (EU) No 1301/2013, (EU) No 1303/2013,
(EU) No 1304/2013, (EU) No 1309/2013, (EU) No 1316/2013, (EU) No 223/2014, (EU) No 283/2014, and Decision No 541/2014/EU and repealing
Regulation (EU, Euratom) No 966/2012, OJ L 193 of 30.7.2018, p.1 <U>https://eur-lex.europa.eu/legal- content/EN/TXT/?qid=1544791836334&amp;uri=CELEX:32018R1046</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.25pt"></TD><TD STYLE="width: 21.25pt">(g)</TD><TD STYLE="text-align: justify">If a change to the <I>contractor</I>&rsquo;s legal, financial, technical, organisational or ownership
situation substantially affects the performance of the <I>APA </I>or substantially modify the conditions under which the <I>APA</I>
was initially awarded or a change regarding the exclusion situations listed in Article 136 of Regulation (EU) 2018/1046 that calls
into question the decision to award the contract.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.25pt"></TD><TD STYLE="width: 21.25pt">(h)</TD><TD STYLE="text-align: justify">In the event of <I>force majeure</I>, where either resuming implementation is impossible or the
necessary ensuing amendments to the <I>APA</I> or a <I>Vaccine Order Form</I> would mean that the tender specifications are no
longer fulfilled or result in unequal treatment of tenderers or contractors.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.14.3.</B></TD><TD STYLE="text-align: justify"><B>Grounds for termination by the contractor</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The <I>contractor</I> may terminate the
<I>APA</I> or the respective <I>Vaccine Order Form</I> in the following circumstances:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.25pt"></TD><TD STYLE="width: 21.25pt">(a)</TD><TD STYLE="text-align: justify">If the <I>Commission</I> or any of the <I>participating Member States</I> [*****].</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.25pt"></TD><TD STYLE="width: 21.25pt">(b)</TD><TD STYLE="text-align: justify">In the event of <I>force majeure</I>, where either resuming implementation is impossible or the
necessary ensuing amendments to the <I>APA</I> or a <I>Vaccine Order Form</I> would mean that the tender specifications are no
longer fulfilled or result in unequal treatment of tenderers or contractors.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.14.4.</B></TD><TD STYLE="text-align: justify"><B>Procedure for termination</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The <I>contractor</I> or the <I>Commission</I>
(as the case may be) must <I>formally notify </I>the <I>Commission</I> or the <I>contractor</I> (as the case may be) of its intention
to terminate the <I>APA</I>. The foregoing sentence shall apply mutatis mutandis to the <I>Vaccine Order Forms</I>, it being understood,
however, that <I>formal notification</I> shall be issued by or to (as the case may be) the relevant <I>participating Member State</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The <I>Party</I> receiving a termination
notice pursuant to the foregoing paragraph shall have thirty (30) calendar days following the date of receipt to submit observations,
including the measures it has taken or will take to continue fulfilling its contractual obligations. Failing that, the decision
to terminate becomes enforceable the day after the time limit for submitting observations has elapsed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the other <I>Party</I> submits observations,
the <I>Party</I> intending to terminate must formally notify it either of the withdrawal of its intention to terminate or of its
final decision to terminate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the cases referred to in points (a)
to (c), (f) and (g) of Article II.14.2 and in Article II.14.3, the date on which the termination takes effect must be specified
in the <I>formal notification</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the cases referred to in points (d),
(e) and (h) of Article II.14.2, the termination takes effect on the day following the date on which the <I>contractor</I> receives
<I>formal notification</I> of termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.14.5.</B></TD><TD STYLE="text-align: justify"><B>Effects of termination</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.85pt"></TD><TD STYLE="width: 20.15pt"><I>(a)</I></TD><TD><I>in case of an automatic termination pursuant to Article II.14.1</I></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.65pt 0pt 0; text-align: justify">No liability is incurred by
any <I>Party</I> in case of an automatic termination according to Article II.14.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.65pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.65pt 0pt 0; text-align: justify">The <I>up-front payment</I>
and the <I>second up-front payments</I> shall [*****] in the following way:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.65pt 0pt 0; text-align: justify; text-indent: 192.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.65pt 0pt 0; text-align: justify; text-indent: 192.75pt"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.65pt 0pt 0; text-align: justify; text-indent: 192.75pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.65pt 0pt 0; text-align: justify">The <I>contractor</I>
shall send to the <I>Commission</I> within sixty (60) days from notifying the <I>Commission</I> about the automatic
termination of the <I>APA</I>, a financial statement (the &ldquo;<B>Financial Statement</B>&rdquo;), detailing for which
expenses the <I>up-front payments</I> have been used in relation to the purposes as set out in the <I>APA</I>. Expenses to be
taken into account include the full amount of internal and/or external expenses which have been, or will be, incurred as well
as such which have been committed by, or relate to commitments made by, the <I>contractor</I> at the time when the <I>contractor</I>
notified the <I>Commission</I>, it being understood that such 'expenses' shall include, without limitation, costs, expenses
and liabilities, write-offs and value adjustments in connection with research, development, ramp up, IP, real estate,
construction, administration, manufacturing, production, packaging, delivery, preservation, transportation, personnel,
redundancy, litigation, agreements, terminations of agreements, advice and services, penalties and fines, whether incurred
directly or indirectly by the <I>contractor</I>, a provider, a contractor or a subcontractor of the <I>contractor</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.65pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.65pt 0pt 0; text-align: justify">In the <I>Financial Statement</I>,
the <I>contractor</I> will set out such amounts as well as those amounts of the <I>up-front payments</I> that have neither been
incurred nor committed (&ldquo;<B>unspent amounts</B>&rdquo;). Such <I>unspent amounts</I> will be reimbursed by the <I>contractor</I>
to the <I>Commission</I> and the <I>participating Member States</I> in proportion to their respective <I>up-front payments</I>
within thirty (30) days from the receipt of the <I>Financial Statement</I> by the <I>Commission</I>, it being understood that the
<I>Financial Statement</I> and the <I>unspent amounts</I> shall be final and binding upon all <I>Parties</I> to the extent the
<I>Commission</I> and the <I>participating Member States</I> have not provided to the <I>contractor</I> a written statement of
objections, specifying in reasonable detail the grounds of objections, within thirty (30) days from the receipt of the <I>Financial
Statement</I> by the <I>Commission</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.7pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the <I>contractor</I> will
transfer, upon the <I>Commission</I>'s request to be provided within forty-five (45) days after the receipt of notification about
the automatic termination, to the <I>Commission</I>, or a third party named by the <I>Commission</I>, any raw materials and primary
components not used and paid for with the <I>up-front payments</I> (the &ldquo;<B>Refundable Items</B>&rdquo;). The <I>contractor</I>
will also facilitate the discussion of a transfer of reserved capacity with <I>CMOs</I> paid for with the <I>up-front payments</I>
to a third party selected by the <I>Commission</I>. [*****].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.85pt"></TD><TD STYLE="width: 20.15pt"><I>(b)</I></TD><TD><I>in case of termination pursuant to Article II.14.2</I></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In case of a termination by the <I>Commission</I>
according to Article II.14.2(a), the provisions on the effect of the termination and refunding of the <I>unspent amounts</I> and
the <I>Refundable Items</I> as set out in Article&nbsp;II.14.5(a) apply mutatis mutandis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In case of a termination of the <I>APA</I>
by the <I>Commission</I> or a <I>Vaccine Order Form</I> by a <I>participating Member State</I> according to Article
II.14.2(b) to (g), the <I>contractor</I> may be liable for damage incurred by the <I>Commission</I> or the <I>participating
Member State</I> [*****]. The <I>Commission</I> or the <I>participating Member State</I> may claim compensation for such
damage, as allowed by applicable laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.85pt"></TD><TD STYLE="width: 20.15pt">(c)</TD><TD><I>in case of termination pursuant to Article II.14.3</I></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The <I>contractor</I> is not entitled to
compensation for any damage resulting from the termination of the <I>APA</I> or a <I>Vaccine Order Form</I>, including loss of
anticipated profits, if the <I>contractor</I> terminated the <I>APA</I> or the relevant <I>Vaccine Order Form</I> in accordance
with Article II.14.3(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The <I>Commission</I> and the <I>participating
Member State</I> are liable for damage incurred by the <I>contractor</I> as a result of the termination of the <I>APA</I> or
a <I>Vaccine Order Form </I>by the <I>contractor</I> on the basis of Article II.14.3(a). The <I>contractor</I> may claim
compensation for such damage against the <I>Commission </I>and/or the <I>participating Member State(s)</I>, as allowed by
applicable laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The <I>Parties</I> must take all appropriate
measures to minimise costs, prevent damage and cancel or reduce their commitments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Within sixty (60) calendar days of the
date of termination, the <I>contractor</I> must submit any report and any invoice required for <I>Products</I> that were provided
before the date of termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Articles I.10.3, I.10.4, I.10.5, I.23,
II.6, II.7 and II.17 shall survive any termination of this <I>APA</I> and/or the <I>Vaccine Order Forms</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 141.75pt"></TD><TD STYLE="width: 32.4pt"><FONT STYLE="font-variant: normal">II.15.</FONT></TD><TD>Payment Requests, Invoices, Value Added Tax and e-invoicing</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.15.1.</B></TD><TD STYLE="text-align: justify"><B>Payment Requests, Invoices and value added tax</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Payment requests and invoices shall contain
the following information: (i) the <I>contractor</I>&rsquo;s full name and address, (ii) the reference to this APA and to the <I>Vaccine
Order Form </I>(to the extent already concluded), (iii) the full name and address of the recipient, (iv) the name of the <I>participating
Member State</I> concerned, (v) the invoiced amount, (vi) the currency, (vii) the quantity of <I>Product doses</I> delivered (or
offered to be delivered if the <I>participating Member State</I> illegitimately refuses acceptance of delivery), or, with respect
to the <I>up-front payment</I>, the <I>second up-front payment</I> and the <I>Additional Doses up-front payment</I>, the quantity
of <I>Product doses</I> allocated to the relevant <I>participating Member State</I> pursuant to Articles I.8.1 through I.8.3, (viii)
the date of delivery (if relevant), and (ix) the date of issuance of the payment request or invoice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Invoices must indicate the place of taxation
of the <I>contractor</I> for value added tax (VAT) purposes and must specify separately amounts not including VAT and amounts including
VAT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The <I>Commission</I> is exempt from all
taxes and duties, including VAT, in accordance with Articles 3 and 4 of the Protocol 7 of the Treaty on the Functioning of the
European Union on the privileges and immunities of the European Union. The <I>Parties</I> shall cooperate in good faith to ensure
the tax exemption of the <I>Commission</I> at all steps of the <I>APA</I> and take all necessary actions to ultimately ensure such
exemption in connection with the execution of the <I>APA</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding the preceding paragraph,
for the avoidance of doubt, VAT may be charged on <I>doses</I> of the <I>Product</I> under the conditions of national legislation.
In such cases, the taxable amount may include the amount paid by the <I>participating Member State</I> as well as the respective
portion of the <I>up-front payment</I> paid by the <I>Commission</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the further avoidance of doubt, the
<I>Parties</I> agree that all prices set forth in the <I>APA</I> shall be exclusive of VAT and that VAT, if any, shall be paid
in addition to the prices set forth in the <I>APA</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.15.2.</B></TD><TD STYLE="text-align: justify"><B>E-invoicing</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Receipt of invoices by standard format
(pdf) or e-mail is accepted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 141.75pt"></TD><TD STYLE="width: 32.4pt"><FONT STYLE="font-variant: normal">II.16.</FONT></TD><TD>Payments</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.16.1.</B></TD><TD STYLE="text-align: justify"><B>Date of payment</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The date of payment is deemed to be
the date on which the <I>Commission</I>&rsquo;s account or the account of the <I>participating Member State</I> in question
is debited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.16.2.</B></TD><TD STYLE="text-align: justify"><B>Currency</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Payments are made in euros.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.16.3.</B></TD><TD STYLE="text-align: justify"><B>Costs of transfer</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The costs of the transfer are borne as
follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.85pt"></TD><TD STYLE="width: 20.15pt">(a)</TD><TD>the <I>Commission</I> or the <I>participating Member State</I> in question bears the costs of dispatch charged by its bank;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.85pt"></TD><TD STYLE="width: 20.15pt">(b)</TD><TD>the <I>contractor</I> bears the costs of receipt charged by its bank;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.85pt"></TD><TD STYLE="width: 20.15pt">(c)</TD><TD>the <I>Party</I> causing repetition of the transfer bears the costs for repeated transfer.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.16.4.</B></TD><TD STYLE="text-align: justify"><B>Suspension of the time allowed for payment</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The <I>Commission</I> or the <I>participating
Member State</I> in question may suspend the payment periods specified in Article I.17 at any time by <I>notifying </I>the <I>contractor</I>
that its payment request or invoice (as the case may be) cannot be processed if the <I>Commission</I> or the <I>participating Member
State</I> in question is not able to process a payment request or invoice (as the case may be):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.85pt"></TD><TD STYLE="width: 20.15pt">(a)</TD><TD>because the payment request or invoice (as the case may be) does not comply with the <I>APA</I>; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 51.85pt"></TD><TD STYLE="width: 20.15pt">(b)</TD><TD>because the <I>Commission</I> or the <I>participating Member State</I> in question has legitimate objections against the documents
submitted with the payment request or invoice (as the case may be).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The <I>Commission</I> or the <I>participating
Member State</I> in question must <I>notify </I>the <I>contractor</I> as soon as possible of any such suspension, giving the reasons
for it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Suspension takes effect on the date the
<I>Commission</I> or the <I>participating Member State</I> in question sends the <I>notification</I>. The remaining payment period
resumes from the date on which the requested information or revised documents are received or the necessary further verification
is carried out. Where the suspension period exceeds two months, the <I>contractor</I> may request the <I>Commission</I> or the
<I>participating Member State</I> in question to justify the continued suspension.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.16.5.</B></TD><TD STYLE="text-align: justify"><B>Interest on late payments of the Commission and/or the participating Member States</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On expiry of the payment periods specified
in Article I.17, the <I>contractor</I> is entitled to interest on late payment at the rate applied by the European Central Bank
for its main refinancing operations in euros (the reference rate) plus five points. The reference rate is the rate in force, as
published in the C series of the <I>Official Journal of the European Union, </I>on the first day of the month in which the payment
period ends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Suspension of the payment period pursuant
to Article II.16.4 is not considered as giving rise to late payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interest on late payment covers the period
running from the day following the due date for payment up to and including the date of payment as defined in Article II.16.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.16.6.</B></TD><TD STYLE="text-align: justify"><B>Interest on late payments of the contractor</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the <I>contractor </I>does not
honour the obligation to pay the <I>unspent amount</I> when due, the amount due bears interest at the rate indicated in
Article II.16.5. Interest on late payments will cover the period starting on the day after the due date for payment and
ending on the date when the <I>Commission </I>or the <I>participating Member State </I>in question receives the full amount
owed. Any partial payment is first entered against charges and interest on late payment and then against the principal
amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 141.75pt"></TD><TD STYLE="width: 32.4pt"><FONT STYLE="font-variant: normal">II.17.</FONT></TD><TD>Checks and audits</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.17.1.</B></TD><TD STYLE="text-align: justify">The <I>Commission</I> and the European Anti-Fraud Office (&lsquo;the OLAF&rsquo;) may check or
require an audit on the performance of the <I>APA</I>. This may be carried out either by OLAF&rsquo;s own staff or by any outside
body authorised to do so on its behalf.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 51.85pt; text-align: justify">Such checks and audits may
be initiated at any moment during the provision of the vaccines and up to five years starting from the payment of the balance of
the last <I>Vaccine Order Form</I> issued under this <I>APA</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 51.85pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 51.85pt; text-align: justify">The audit procedure is initiated
on the date of receipt of the relevant letter sent by the <I>Commission</I>. Audits are carried out on a confidential basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 51.85pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.17.2.</B></TD><TD STYLE="text-align: justify">The <I>contractor</I> must keep all original documents stored on any appropriate medium, including
digitised originals if authorised under national law, for a period of five years starting from the payment of the balance of the
last <I>Vaccine Order Form</I> issued under this <I>APA</I>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.17.3.</B></TD><TD STYLE="text-align: justify">The <I>contractor</I> must grant the appropriate right of access to sites and premises where the
<I>APA</I> is implemented and to all the information, including information in electronic format, needed to conduct such checks
and audits. The <I>contractor</I> must ensure that the information is readily available at the moment of the check or audit and,
if so requested, that information is handed over in an appropriate format.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.17.4.</B></TD><TD STYLE="text-align: justify">On the basis of the findings made during the audit, a provisional report is drawn up. The <I>Commission</I>
or its authorised representative must send it to the <I>contractor</I>, who has 30 days following the date of receipt to submit
observations. The <I>contractor</I> must receive the final report within 60 days following the expiry of the deadline to submit
observations.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.17.5.</B></TD><TD STYLE="text-align: justify">In accordance with Council Regulation (Euratom, EC) No 2185/96 of 11 November 1996 concerning on-the-spot
checks and inspection carried out by the <I>Commission</I> in order to protect the European Communities&rsquo; financial interests
against <I>fraud </I>and other <I>irregularities </I>and Regulation (EU, Euratom) No 883/2013 of the European Parliament and of
the Council of 11 September 2013 concerning investigations conducted by the European Anti-Fraud Office, the European Anti- Fraud
Office may carry out investigations, including on the spot checks and inspections, to establish whether there has been <I>fraud</I>,
corruption or any other illegal activity under the contract affecting the financial interests of the Union. Findings arising from
an investigation may lead to criminal prosecution under national law.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 51.85pt; text-align: justify">The investigations may be carried
out at any moment during the provision of the vaccines and up to five years starting from the payment of the balance of the last
<I>Vaccine Order Form</I> issued under this <I>APA</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 51.85pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.17.6.</B></TD><TD STYLE="text-align: justify">The Court of Auditors and the European Public Prosecutor&rsquo;s Office established by Council
Regulation (EU) 2017/1939<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>5</SUP></FONT> (&lsquo;the
EPPO&rsquo;) have the same rights as the <I>Commission</I>, particularly right of access,
for the purpose of checks, audits and investigations.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 51.85pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 51.85pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><SUP>5</SUP></FONT>
Council Regulation (EU) 2017/1939 of 12 October 2017 implementing enhanced cooperation on the establishment of the European Public
Prosecutor&rsquo;s Office</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 51.85pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 51.85pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 51.85pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 51.85pt"><B>II.17.7.</B></TD><TD STYLE="text-align: justify">The <I>Commission</I> and/or any <I>participating Member State</I> shall have the right to use,
at their exclusive costs, an internationally recognised expert (not engaged on a contingent basis) to perform an audit in order
to verify (a) any clinical trial data, and/or (b) the manufacturing conditions including by subcontractors. The <I>contractor</I>
will enable such an audit and will make available to the third-party auditor, upon reasonable request, any documents or information
for that purpose.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>*** Signature page to follow ***</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This <I>APA</I> has been executed on the
place and dates mentioned hereunder, in two original copies, each of the <I>contractor </I>and the <I>Commission</I> acknowledging
having received one original signed copy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the <I>contractor</I>,</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the <I>Commission</I>,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt">[*****]</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt">[*****]</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt">[*****]</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt">[*****]</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt; width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; font-size: 10pt; width: 42%">/s/ [*****]</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt; width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; font-size: 10pt; width: 42%">/s/ [*****]</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Done
at [*****]</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Done
at [*****]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt">[*****]</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt">[*****]</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; font-size: 10pt">/s/ [*****]</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Done at [*****]</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Annex
I&nbsp;&nbsp;<BR>
List of participating Member States</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: #D9D9D9">
    <TD STYLE="width: 25%; border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt"><B>Full name</B></TD>
    <TD STYLE="width: 25%; border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt"><B>Contact person</B></TD>
    <TD STYLE="width: 25%; border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; padding: 2.85pt 0.75pt"><B>Full official address</B></TD>
    <TD STYLE="width: 25%; border-top: black 1pt solid; border-right: black 1pt solid; padding: 1.5pt 3pt"><B>Email address</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">Republic of Austria</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; padding: 2.85pt 0.75pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">Kingdom of Belgium</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; padding: 2.85pt 0.75pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">Republic of Bulgaria</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; padding: 2.85pt 0.75pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">Republic of Croatia</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; padding: 2.85pt 0.75pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">Republic of Cyprus</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; padding: 2.85pt 0.75pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">Czech Republic</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; padding: 2.85pt 0.75pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">Kingdom of Denmark</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; padding: 2.85pt 0.75pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">Republic of Estonia</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; padding: 2.85pt 0.75pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">Republic of Finland</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; padding: 2.85pt 0.75pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">French Republic</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; padding: 2.85pt 0.75pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">Federal Republic of Germany</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; padding: 2.85pt 0.75pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">Hellenic Republic</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; padding: 2.85pt 0.75pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">Hungary</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; padding: 2.85pt 0.75pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">Ireland</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; padding: 2.85pt 0.75pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">Italian Republic</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; padding: 2.85pt 0.75pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">Republic of Latvia</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; padding: 2.85pt 0.75pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">Republic of Lithuania</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; padding: 2.85pt 0.75pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">Grand Duchy of Luxembourg</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; padding: 2.85pt 0.75pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">Republic of Malta</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; padding: 2.85pt 0.75pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">Kingdom of the Netherlands</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; padding: 2.85pt 0.75pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">Republic of Poland</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; padding: 2.85pt 0.75pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">Portuguese Republic</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; padding: 2.85pt 0.75pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">Romania</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; padding: 2.85pt 0.75pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">Slovak Republic</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; padding: 2.85pt 0.75pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">Republic of Slovenia</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; padding: 2.85pt 0.75pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">Kingdom of Spain</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; padding: 2.85pt 0.75pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">Kingdom of Sweden</TD>
    <TD STYLE="border-top: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD>
    <TD STYLE="border: black 1pt solid; padding: 2.85pt 0.75pt">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding: 1.5pt 3pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Annex
II&nbsp;&nbsp;<BR>
Template Vaccine Order Form</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 22.7pt">1.</TD><TD>[Name of Member State] (the <B>&ldquo;Member State&rdquo;</B>), represented for the purposes of signing this specific order
form by [<I>forename, surname, function, department of authorising officer</I>],</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 22.7pt">2.</TD><TD>CureVac AG</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.7pt">Friedrich-Miescher-Stra&szlig;e 15, 72076 T&uuml;bingen</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.7pt">[<I>VAT registration number</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(<B>&quot;the contractor&quot;</B>), represented for the purposes
of signing this specific order form by [<I>forename, surname and function of legal representative</I>,]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WHEREAS, the <I>contractor</I> and the
<I>Commission</I> acting on behalf of and in the name of the <I>participating Member States</I> entered into that Advance Purchase
Agreement for the production, purchase and supply of Vaccine against <I>COVID-19</I> in the European Union dated [l] September
2020 (the <B>&ldquo;APA&rdquo;</B>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WHEREAS, the <I>APA</I> provides that each
<I>participating Member State</I> will execute an order form with the information filled in (a <B>&ldquo;Vaccines Order Form&rdquo;</B>);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WHEREAS, in line with the conditions set
out in the <I>APA,</I> the <I>Member State</I> wishes to order <I>doses</I> of the <I>Product</I> from the <I>contractor</I> in
accordance with the terms of the <I>APA</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WHEREAS in accordance with the provisions
set out in the APA, the <I>contractor</I> has agreed to supply the <I>doses</I> of the <I>Product</I> allocated to each <I>participating
Member State</I> in a given timeframe, should it manage to obtain a (conditional) <I>EU marketing authorisation</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WHEREAS defined terms used but not defined
herein shall have the meaning ascribed to them in the <I>APA</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">HAVE AGREED</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>Article 1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>Subject matter</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>1.1</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
<I>Vaccine Order Form</I> is entered into as contemplated by the APA, signed by the <I>Commission</I>, acting on behalf and in
the name of the <I>participating Member States</I> and the <I>contractor</I> on [<I>complete date</I>]<I>.</I> This <I>Vaccine
Order Form</I> is an integral part of the APA and the terms and conditions of the APA are incorporated into this <I>Vaccine Order
Form</I> by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>1.2</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
line with the terms and conditions of the <I>APA</I>, the undersigned <I>Member State</I> hereby purchases [insert the number of
doses] <I>doses</I> of the <I>Product</I> in accordance with Article I.8 of the <I>APA</I> and re-confirms to be obliged to perform
all obligations imposed on the <I>Member State</I> by the <I>APA</I> with respect to such purchase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>Article 2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>Price, method of payment
and invoicing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2.1</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Price per does shall equal the price as determined in Article I.16 of the <I>APA</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2.2</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
payments to the <I>contractor</I> under this <I>Vaccine Order Form</I> shall be made in accordance with Article I.17 of the <I>APA</I>
and they shall be made by deposit of Euros by wire transfer of immediately available funds in the requisite amount to the bank
account referred to in Article I.18 of the APA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2.3</B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Invoices
shall be issued in accordance with Article II.15 of the APA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>2.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>The
undersigned <I>Member State</I> hereby undertakes to comply with the payment obligations referred to in the APA, including but
not limited to the payments as set forth in Article I.17.2 of the APA, with respect to the quantities of <I>doses</I> allocated
to the undersigned <I>Member State</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>Article 3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>Distribution</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>The
delivery hub for the undersigned <I>Member State</I> is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[<I>Member State to enter unique location
of the delivery hub</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.2</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The <I>contractor</I>
shall notify the representative of the undersigned <I>Member State</I> in good time prior to such time that the <I>contractor</I>
expects <I>doses</I> of the <I>Product</I> to be delivered. The first notification should be done up to [*****] weeks before
the start of the first delivery and continue on a rolling basis. Such notifications shall include an estimate of the number
of <I>doses</I> expected to be delivered and the expected dates that such <I>doses</I> will be available to be shipped to the
delivery hub designated by the undersigned <I>Member State</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The <I>contractor</I> shall deliver the
<I>doses</I> of <I>Product</I> at the unique point of delivery indicated by the undersigned <I>Member State</I>. For the avoidance
of doubt, the undersigned <I>Member State</I> shall bear the costs of setting up of the delivery hub and the distribution of the
<I>Product</I> as of the delivery hub.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>Article 4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>Communication details;
Notices</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any notice given under this <I>Vaccine
Order Form</I> shall be in writing in English, shall refer to the <I>APA</I> and this <I>Vaccine Order Form</I> and shall be sent
by either pre-paid post/pre-paid airmail or courier to the principal office or registered office of the recipient or by electronic
transmission (e-mail and/or pdf) to the addresses set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If to the <I>Member State</I> to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt">[<I>Full name</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt">[<I>Function</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt">[<I>Name of Participating Member State</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt">[<I>Full official address</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt">E-mail: [<I>complete</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If to the <I>contractor</I> to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt; text-align: justify">[*****]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt; text-align: justify">CUREVAC AG</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt; text-align: justify">Friedrich-Miescher-Str. 15,
72076 T&uuml;bingen, Deutschland</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt">E-mail: [*****]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.3pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>Article 6</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>Indemnification</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The undersigned <I>Member State</I> acknowledges and agrees
to be bound by the provisions of Article I.23 of the APA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>Article 7</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>Termination</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This <I>Vaccine Order Form</I> shall remain
in full force and effect until all obligations under this <I>Vaccine Order Form</I> are duly fulfilled, unless and to the extent
this <I>Vaccine Order Form</I> is terminated in accordance with the <I>APA</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>*** Signature page to follow ***</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This <I>Vaccine Order Form</I> has been
executed on the place and dates mentioned hereunder, in two original copies, each of the <I>contractor </I>and the <I>Member State</I>
acknowledging having received one original signed copy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the <I>contractor</I>,</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the <I>Member State,</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<FONT STYLE="background-color: #D2D2D2"><I>forename/surname/position</I></FONT>]</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<FONT STYLE="background-color: #D2D2D2"><I>forename/surname/position</I></FONT>]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt; width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; font-size: 10pt; width: 42%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt; width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; font-size: 10pt; width: 42%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Done
    at [<FONT STYLE="background-color: #D2D2D2"><I>place</I></FONT>], [<FONT STYLE="background-color: #D2D2D2"><I>date</I></FONT>]</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Done
    at [<FONT STYLE="background-color: #D2D2D2"><I>place</I></FONT>], [<FONT STYLE="background-color: #D2D2D2"><I>date</I></FONT>]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<FONT STYLE="background-color: #D2D2D2"><I>forename/surname/position</I></FONT>]</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U></U></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Done
    at [<FONT STYLE="background-color: #D2D2D2"><I>place</I></FONT>], [<FONT STYLE="background-color: #D2D2D2"><I>date</I></FONT>]</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>Annex
III&nbsp;&nbsp;<BR>
Annex 7 to Commission Decision C(2020) 4192 final of 18 June 2020 - Agreement between the Commission and Member States on procuring
COVID-19 vaccines on behalf of the Member States and related procedures</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B></B></FONT></P>

<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 15%"><IMG SRC="tm213031d1_10-ximg016.jpg" ALT="">&nbsp;</TD>
    <TD STYLE="width: 15%">EUROPEAN<BR>
COMMISSION</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">Brussels, 18.6.2020</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">C(2020)
4192 final</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">ANNEX</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>ANNEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B><I>to the</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>Commission Decision</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>on approving the agreement
with Member States on procuring Covid-19 vaccines on behalf of the Member States and related procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 33%"><FONT STYLE="font-size: 10pt"><B>EN</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 34%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 33%"><FONT STYLE="font-size: 10pt"><B>EN</B></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><I>16.06.2020</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Preamble</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Having regard to Article 4(5)(b) of Council
regulation (EU) 2016/369 on the provision of emergency support within the Union<SUP>1</SUP> as amended by Council regulation (EU)
2020/521 of 14 April 2020 activating the emergency support under regulation (EU) 2016/369, and amending its provisions taking
into account the COVID-19 outbreak (hereinafter &#8220;ESI&#8221; or &#8220;ESI regulation&#8221;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">***</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The European Commission (&#8220;the Commission&#8221;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35pt 0pt 0">The following Member States: (XXX), hereinafter referred
to as &#8220;the Participating Member States&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Together referred to as &#8220;the Parties&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Agree on the Following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Article 1: Objective and mandate of the Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On the basis of the present agreement,
the Commission is mandated to conclude, on behalf of the Participating Member States, Advance Purchase Agreements (&#8220;APA&#8221;)
with vaccine manufacturers with the objective to procure vaccines for the purposes of combatting the COVID 19 pandemic at Union
level.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Annex to this agreement sets out the negotiating directives
for this purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Article 2: Acquisition of vaccine doses</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is the Participating Member States,
and not the Commission, that shall acquire vaccine doses from the manufacturers on the basis of the APAs unless otherwise agreed.
All relevant vaccination policies shall therefore remain matters for the Participating Member States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Article 3: APAs containing a right to acquire vaccine
doses</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Where the Commission concludes an APA in
conformity with the present agreement that provides the right for the Participating Member States to acquire vaccine doses, the
use of such a right shall take place by means of the conclusion of contracts between the Participating Member States and the vaccine
manufacturers. There shall be no obligation for any Participating Member State
to conclude such a contract on the basis of the APA. The APA shall contain a clause to this end.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 47; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Article 4: APAs containing an obligation to acquire
vaccine doses</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify">Where the Commission intends to
conclude, in conformity with the present agreement, an APA containing an obligation to acquire vaccine doses, it shall inform the
Participating Member States of such intention and the detailed terms. In case a Participating Member State does not agree with
the conclusion of an APA containing an obligation to acquire vaccine doses or its terms, it has the right to opt out by explicit
notification to the Commission within 5 working days after the Commission has communicated its intention to conclude the APA. All
Participating Member States not having opted out within the period of 5 working days are deemed to have authorised the Commission
to negotiate and conclude the APA with the vaccine manufacturer in their name and on their behalf.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Article 5: The legally binding nature of APAs</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify">Once concluded, the terms of the
APA shall be legally binding on the Participating Member States, except for those who have exercised their right to opt out.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Article 6: Responsibility and liability</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify">The present Agreement regulates
only the division of potential liability and indemnification between the Commission and the Participating Member States. It does
not regulate the extent to or the conditions under which potential liability of the vaccine manufacturer may be taken over or indemnified
under the APAs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify">The Commission shall be exclusively
responsible for the procurement process and the conclusion of APAs including any liability arising out of the conduct of the negotiations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Participating Member States acquiring a
vaccine shall be responsible for the deployment and use of the vaccines under their national vaccination strategies, and shall
bear any liability associated with such use and deployment. This shall extend to and include any indemnification of vaccine manufacturers
under the terms and conditions of the relevant APA for liability related to the use and deployment of vaccines normally borne by
such manufacturer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Article 7: Obligation not to negotiate separately</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify">By signing the present Agreement,
the Participating Member States confirm their participation in the procedure and agree not to launch their own procedures for advance
purchase of that vaccine with the same manufacturers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify">In case an APA containing an obligation
to acquire vaccine doses has been concluded with a specific manufacturer, the Member States having made use of the opt-out provided
under the present Agreement can enter into separate negotiations with the same manufacturer after the APA under the present Agreement
has been signed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 48; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>Annex</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Initial considerations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A permanent solution to the COVID-19 crisis
is most likely to be brought about by the development and deployment of a safe and effective vaccine against the virus. Every month
gained in the deployment of a vaccine will save many lives, many jobs and billions of euros.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Therefore, it is the objective of the present
Agreement that the EU takes steps to secure sufficient supplies of a safe and effective vaccine for Member States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Structure and purpose of the procurement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Work on a COVID-19 vaccine is challenging
for many reasons: the shortened development timeframe, the large upfront costs for manufacturers, the high failure rate during
clinical trials. If vaccine producers follow their usual practice of making investments in production capacity only when they are
sure of a viable product, this will result in considerably longer waiting times for a vaccine. Investments need to be made now
in order to ensure that vaccines are being produced at the scale required as early as possible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the present agreement, this challenge
will be addressed through concluding EU-level Advance Purchase Agreements (&#8220;APA&#8221;) with vaccine manufacturers when necessary,
to secure access to vaccine candidates where they are successful, including up-front EU financing to de-risk essential investments
to increase the speed and scale of manufacturing successful vaccines. Funding for the up-front payments will come from the Emergency
Support Instrument (ESI).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Parties understand that developing
a safe and effective vaccine is a highly complex process and the risk of failure in any such venture is very high. Therefore, the
aim is to put in place APAs with a number of manufacturers of leading vaccine candidates, to maximise the chances of having access
to at least one successful vaccine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Commission will invite all vaccine
manufacturers to manifest interest. In general, the Commission will give priority to negotiating specific APAs with those manufacturers
that (a) have entered or have firm plans to enter clinical trials still in 2020, (b) have the capacity to develop a successful
vaccine and (c) have a proven capacity to produce at scale already in 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Process and governance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to run the procurement centrally
and efficiently, the European Commission will set up a steering board for the process subject to Article 6 of the present Agreement.
It will be co-chaired by the European Commission and a Participating Member State with experience in the negotiations and production
capacities for vaccines. The steering board will include senior officials from all Participating Member States to assist and provide
guidance throughout the evaluation process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The co-chairs of the steering board
will propose a team of a limited number of experts with relevant experience for the ongoing negotiations from six
Participating Member States with production capacities for vaccines. These experts will join with the European Commission in
a negotiation team (&#8220;joint negotiation team&#8221;), which will work on a continuous basis as one unit. That joint
negotiation team will start work immediately building on previous contacts with individual companies by the European
Commission and Participating Member States. In order to launch negotiations with a specific manufacturer, there needs to be
support from at least four Participating Member States. The joint negotiation team will make its best effort to take the
advice of the steering board into account in the negotiations and will report back to the steering board on a regular basis
on the progress made in negotiating with individual companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 49; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For compliance with the applicable rules,
all members of the steering board and the joint negotiation team will obtain the status of experts associated to the procurement
process as provided in the Financial Regulation. Given their access to highly sensitive business information, all those members
will be required to sign strict confidentiality and no-conflict-of-interest agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assisted by the steering board, the European
Commission will then decide which of the resulting APAs should be concluded, in particular if financing under ESI is insufficient
to finance all relevant packages. The Commission will only consider those APAs for financing where at least four Participation
Member States have expressed agreement. Before making any final decisions, the Commission will seek independent scientific advice
on the state of progress and the available data on quality, safety and efficacy for the vaccine candidate in question.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Should financing under ESI be insufficient,
Participating Member States can decide to top up ESI funding to make up the gap to finance all packages. In such a case where there
are opportunities to conclude further APAs but money from ESI is no longer sufficient, Participating Member States will have the
opportunity to express their interest in such opportunities. If at least four Participating Member States express interest, those
Participating Member States will make use of the possibility of a voluntary contribution to ESI to the required amount allowing
the Commission to proceed with signing the APA only on behalf of those Member States that have expressed interest and contributed
the funds to ESI.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For full transparency, the European Commission
will report to the IPCR at least once every two weeks on overall progress more generally.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Advanced Purchase Agreements and conditions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To conclude APAs, the joint negotiating
team will negotiate funding packages with individual vaccine producers in return for the right to buy a specific number of vaccine
doses in a given timeframe and at a certain price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As outlined in the present Agreement, the
European Commission also has the possibility to conclude APAs including an obligation to procure the vaccine if it becomes available,
where the conditions (notably the pricing) of those APAs make this worthwhile and in line with the conditions in the present Agreement.
If in such a case the distinction between upfront payments and purchase price is difficult to draw, the Commission will share the
total cost related to the vaccine purchase but will in any case contribute no more than 50% of the total cost.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Funding provided up front will be considered
as an advance payment for any eventual purchase by Member States, thus reducing the amount that Member States will have to pay
when eventually purchasing that vaccine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The up-front payments under the APAs
shall be used by manufacturers to de-risk the necessary investments related to both vaccine development and clinical trials,
and the preparation of the at-scale production capacity along the entire vaccine production value chain in the EU required
for a rapid deployment of millions of doses of an eventual vaccine. The relevant payments should be structured according to
the need of the manufacturer, but subject to the state of the vaccine development, in particular relying on transparency of
the associated clinical data and its assessment, at the time of payment. This is in order to avoid obligations to pay in
situations where the development work has shown a vaccine candidate likely to be unsuccessful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 50; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The purchase price of the vaccine, as well
as the amount of funding provided up front will take into account a transparent estimation of production costs (supported by independent
audits where available), as well as the resources already granted from other public sources. Under the APA, the manufacturer can
be asked to provide ex post proof supported by independent audits concerning the activities financed by these payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aim of the negotiation is to conclude
APAs with individual companies under the best possible conditions. These APAs should specify details with respect to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18.35pt"></TD><TD STYLE="width: 17.65pt">a)</TD><TD STYLE="text-align: justify">Payments to be made, such as payment amounts, payment schedules, type of payments requested and
the use of those payments related to de-risk investment, financing clinical trials, providing working capital and scaling-up production
capacity;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18.35pt"></TD><TD STYLE="width: 17.65pt">b)</TD><TD STYLE="text-align: justify">Delivery details of the vaccine if successful, such as price per person immunised (or alternatively,
number of doses required per person immunised and price per dose), quantity of doses to be delivered and delivery timeline following
approval; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18.35pt"></TD><TD STYLE="width: 17.65pt">c)</TD><TD STYLE="text-align: justify">Any other relevant conditions, such as production capacity built or used in the EU or liability
arrangements.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For liability arrangements, the joint negotiation
team will make its best effort to limit what is required by individual companies for the purpose of indemnification to be included
in the terms and conditions of the APA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The APAs will contain provisions to clarify
the law applicable to both the APA and resulting purchase orders as well as the competent courts. The Participating Member States
agree that each APA negotiated by the Commission on their behalf with a vaccine manufacturer will have the same applicable law
for all Participating Member States, and that the courts corresponding to that applicable law will be competent to hear disputes
arising from that APA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When taking a decision to finance individual
APAs, the European Commission, in consultation with the steering board, will take into account the following elements: any available
data on quality, safety and efficacy of the vaccine at time of negotiation of the contract, speed of delivery at scale, cost, risk-sharing,
diversification of technologies, capacity to supply through development of production capacity within the EU, possible flexible
future use of any capacity funded, engagement at an early stage with EU regulators with the intention to apply for an EU marketing
authorisation for the candidate vaccine(s), commitment to supply vulnerable countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The procedure outlined above complies
with the ESI Regulation and the Financial Regulation. The latter is aligned to the European procurement Directives, which also
provide the basis for national procurement rules. Participating Member States may rely on the procedure run by the European Commission
to directly purchase vaccines from the manufacturers as and when any of the vaccines becomes available based on the conditions
laid down in the APA. Access to vaccine doses will be allocated to Participating Member States according to the population distribution
key.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the negotiations with the pharmaceutical
industry under the present Agreement, the Commission will promote a Covid-19 vaccine as a global public good. This promotion will
include access for low and middle income countries to these vaccines in sufficient quantity and at low prices. The Commission will
seek to promote related questions with the pharmaceutical industry regarding intellectual property sharing, especially when such
IP has been developed with public support, in order to these objectives. Any vaccines available for purchase under the APAs concluded
but not needed and purchased by Participating Member States can be made available to the global solidarity effort.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 51; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>




<P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"><FONT STYLE="font-variant: small-caps"><B>Annex
IV</B></FONT></P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"><FONT STYLE="font-variant: small-caps"><B>Preliminary
Specification Of The Product</B></FONT></P>

<P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">[*****]</P>

<P STYLE="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<!-- Field: Page; Sequence: 52; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>Annex
V&nbsp;&nbsp;<BR>
List of (planned) manufacturing network partners</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">[*****]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 53; Options: NewSection; Value: 53 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Annex
VI&nbsp;&nbsp;<BR>
Goods Received Form<BR>
</B></FONT><FONT STYLE="font-size: 10pt">(preliminary)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="width: 15%">&nbsp;</TD>
    <TD STYLE="padding-left: 0.025in; border: Black 1pt solid; vertical-align: top; text-align: left; width: 25%"><P STYLE="margin-top: 0; margin-bottom: 0"><B>Receiver</B></P>
                                                      <P STYLE="margin-top: 0; margin-bottom: 0"><B></B> XXX</P>
                                                      <P STYLE="margin-top: 0; margin-bottom: 0">Street</P>
                                                      <P STYLE="margin-top: 0; margin-bottom: 0">City</P>
                                                      <P STYLE="margin-top: 0; margin-bottom: 0">Country</P></TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="padding-left: 0.025in; border: Black 1pt solid; width: 25%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Shipper</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CureVac</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Street</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">City</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Country</P></TD>
    <TD STYLE="width: 15%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B></B>&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Acknowledgment
of goods received</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Product and name:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>[COMMERCIAL NAME] &ndash; CureVac Covid-19
Vaccine</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shipment number:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;______________________ </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Courier Services:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ______________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To whom it may concern</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The undersigned hereby acknowledge receipt of goods (Covid-19
vaccine) of shipment referenced above and declare after visual inspection that (check one of the following)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;</TD><TD>said goods <B>do not present apparent defects</B> upon initial visual inspection and <B>are complete </B></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;</TD><TD>said goods <B>present some apparent defects</B> upon initial visual inspection (see description on next page)</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;</TD><TD>said goods <B>do not appear complete </B>(see description on next page)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Receiver</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Name (CAPITALS)<BR>
Signature</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 1.625in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Date</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border: Black 1pt solid">Please provide a copy of this completed
form to the courier and send any other documentation of apparent defects such as photographs via E-Mail to CureVac Logistics [*****]
(shipment number in email title) as soon as possible and no later than four (4) calendar days after delivery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><IMG SRC="tm213031d1_10-ximg010.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 54; Value: 53 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="border-bottom: Black 1pt solid; font: italic bold 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; font-style: normal">Visual
inspection checklist</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 14.2pt"></TD><TD STYLE="width: 18pt"><B>1.</B></TD><TD><B>Quantity received</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.2pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 50.2pt"></TD><TD STYLE="width: 18pt">a.</TD><TD>Concentrated vaccine _____________ pallets / boxes (circle as appropriate)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 50.2pt"></TD><TD STYLE="width: 18pt">b.</TD><TD>Diluent _____________ pallets / boxes</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 50.2pt"></TD><TD STYLE="width: 18pt">c.</TD><TD>Package inserts (information leaflets) _____________ pallets / boxes</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 14.2pt"></TD><TD STYLE="width: 18pt"><B>2.</B></TD><TD><B>Temperature check</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 32.2pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 32.2pt">Temperature indicated on measurement device:
_________&deg;C</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 32.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 32.2pt">Evidence of temperature excursion: (Yes/No):
___________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 14.2pt"></TD><TD STYLE="width: 18pt"><B>3.</B></TD><TD><B>Apparent defects</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 5%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-size: 10pt"><U>No <FONT STYLE="font-style: normal; font-weight: normal">apparent
    defect</FONT></U></FONT></TD>
    <TD STYLE="font-size: 10pt; width: 5%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-size: 10pt"><U>Some <FONT STYLE="font-style: normal; font-weight: normal">apparent
    defect</FONT></U></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="padding-bottom: 5pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT> No apparent defect
    visible</TD>
    <TD STYLE="padding-bottom: 5pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="font-size: 10pt">
    Broken or damaged boxes</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="padding-bottom: 5pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 5pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="font-size: 10pt">
    Absence of labelling or mis-labelling</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="padding-bottom: 5pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 5pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="font-size: 10pt">
    Leakage</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="padding-bottom: 5pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 5pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="font-size: 10pt">
    Temperature of goods received</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="font-size: 10pt">
    Other: _______________________</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="border: Black 1pt solid; padding-left: 0.025in">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Comments or short description of apparent defects or of elements
        apparently missing</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I></I>&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><I>PLEASE PROVIDE PHOTOGRAPHS
OF APPARENT ISSUE SEPARATELY IN </I></FONT><I>EMAIL</I>&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><IMG SRC="tm213031d1_10-ximg010.jpg" ALT="">&#8239;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 55; Value: 53 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Annex
VII&nbsp;&nbsp;<BR>
Description of the contractor's intended utilisation of the up-front payment and the second up-front payment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[*****]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 56; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm213031d1_10-ximg010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm213031d1_10-ximg010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  X (H# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BJU]?VV
MFVK7-W*(XE[GN?0#N:YT>(M5UG<-"T[$.=OVFX( !]A_^OZ5E4K0@[/?LM6;
MTL/4J+F6B[O1'5T5QL_AN]EB\[7?$3K%G!56VID^YP/TKK;6W6UM(;="2D2*
MBENI &.:5.I*;?-&WS7Y!6I0@ERSYO1.WWO<EHJL=1LA;&Y-Y!Y .TR^8-N?
M3/2H1K>DL0!J=F2>@\]?\:T<XK=K[S-4YO:+^Y_Y%^BHYIX;>(RS2I'&.KNP
M 'XFJJ:UI<CJB:E:,S'  G4DG\Z'**T;$H2DKI/[B]15:+4+*>ZDM8KN"2XC
MSOB60%UQP<CJ*J:_K=OH&E/>S@L<[8T'5W/0?I^E:*+;LC*52$8N;>B$NO$N
MD65^UC/>!;E0&:,(S8'N0,4Z+Q%HLS;4U2T#?W6E"G\C6%X2TU-+B75-5E U
M357XW]1G+!1[G&3^ KK)8(IEQ+$D@]'4&KG&$78PHSK5(\SLO+7;I?7>PZ.2
M.5=T;JZ^JG(IU<S,G@TR,?M&EP2@X+07"PL#]5(-.M;&^"_:=%\0_;+;)Q%=
M$3H?;S!\PQ^-+D7IZHI5G>UD_1I_@=)17/MXF_L^9(==M&T\N<).'\R%S_O
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:]FE,A '^L!1EVGVRP;ZJ*M444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tm213031d1_10-ximg014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm213031d1_10-ximg014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !2 * # 2(  A$! Q$!_\0
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M?\$[?#VW_H->)+2]9?KYE]-G\J]'\+:U\2?#2JUEXG_X)G^"D'0:>]E))']
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MJ%ID;-*^-7PTFFN5Q_";R*-68#IDRGZUTOAWP+X=>9;JP\,?LNWMX_)E\/\
MB^309W]]KN[*?J*^>]#_ ."QGP6BC46_[67Q@NPGW4\2^";+4E_X$9 2:ZC3
M?^"O'P4U&+;/\;OAUJ1;JVJ?#>&V9OJ85%(5F?4WA72/$H4+:>&OB#;K_#'X
M;^+QU2#\(B$4_0UZC^SS;^)(?C'H_P!OLOBU:6@\[S1KNBZ6UI_J),;[M&-P
M.<8V]6V@\$U\,6W_  4:_9^\1'%Q\0_V9YPW>ZTC5K5S_P!^G %?17["'Q_^
M$_Q$^/\ X<M/!^J_"&^U"X^T^3_PCEYJ'VAR+69FV1S$J?E#9ST7/?%(1]^4
J444A!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>tm213031d1_10-ximg016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm213031d1_10-ximg016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !E ,@# 2(  A$! Q$!_\0
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MY.BZ6>'C!7&2O02-R23]Q.X^:L^]-SILMKK7BMDNM25LZ7HMB"P20CJ!U>0
M\M]U><5>>631[N'4]2CBN_$]\ODV%A&_%JAQE1[#K))CMQQ@4 =E;>9]FC\[
M9YNT;]GW=V.<>V:DID <0)YA4R;1O*C )[X'I3Z0PHHHH *^4[Y=,N$DO(8I
M(]$U%O*NH5.6TRZP=KCU3J1ZKO7J,U]65\MG4K:6UNM9LK")K:4_9];TO)V
M$@K,G=5+=#_ PQT(%-"9[)\ _'K:[X?_ +'OY@=8T@>6X+9,\7&R13_$,$#/
MT/>O0*^9='OY?!OB*UO;*5KFZTV$7%E)CY=4L3]Z,^CHNX=\;&'\ S](:+K$
M'B#2+:]M7$EO=1B6-AW!&?SH8(M4444AA1110 4444 >>?'OQ'K^@1:8-$U"
MPTY9O-^T27,T$><;-NWS#SU;.T'M[5Y=<^)_$5T/],^(6GVP[B&ZD8_^0H_Z
MUV_[4XM&?0!<Z;?:DY^T>6MO/Y07_59W#8Q/;H1T/7/'G.GZ/-,?]$^'=S<'
MLT_VN0#ZX*BJ1(7,VG79_P!/^(.J7?\ >$=K<29_%V7^55XU\ VLFZ:?Q7J#
M=]L<,2M^9)K?MM)\30@>5X&\-6GH;BW0$?7SI#5ZVU#QI8_=U/P;H>/22S3;
M^0:@"+0I?#\\"MI7PUUC4U[2S/(P;ZG#+72Z;)KJX.F_"_2+(]GEDA4CZY"F
MLB+5-:N#_P 3/XHZ-;>UFZS?^@A:_*G_ (*G?\%7?C/^S!^V1K_@KP3X^-]X
M;T^ULI8)9;?<7:2WCD?J<_>)_*O9R/(\3FV(>&PK7,E?5V5E9=GW/+S;-Z&6
MT57Q%[-VT^;_ $/V&CF^)5Y%LAL?"VE+SC<[L5_[Y)'Z5GZIH7C2!6;5_'FD
MZ3%_%Y<2+M^A(4_K7\^=U_P6[_:"O?\ 7>)--E_W].1OYT6?_!;#XXV; _;/
M"\K?WI=&1L_AG'Z5];_Q"_./YH?>_P#Y$^;_ .(@Y9VG]R_S/WMO8O!]K(&\
M0^.=3\28Z6Z2R-$WX+N_]"%=;H.H:E<Z=]E\(^%HM!LI5P+Z_58<?[0B&6<^
MA8X]:_ ;1O\ @O\ ?M#^'FS97G@>U;^_'X7M0WY[<U)X@_X.%?VG?$D!BF\5
MZ-%$1ADM]&@AW?4J ?UH_P"(7YQ_-#_P)_\ R(?\1 RSM/[E_F?OKH4,7A;5
M[BUTZ5_%?BZ08NKNX?$=FOH[<^6N0<(N6/\ +2LBG@^_:WW+K7C#4U\V1L;0
MB9P,GGRX%Z =3V!)K^?K1?\ @X+_ &E/#.D?9M.UCPK86[DC=#X=MP6;C)+$
M'+<CDY/2D\/_ /!PA^TKX:68VVO^&S+<OYD\\NA022S'_:8C)QV'0=J/^(7Y
MQ_-#_P "?_R(?\1!RSM/[E_F?T;VRR);1B5@\H4!V48#'') [5)7\ZO_ !$=
M?M0_]#%X8_\ "?M_\*/^(CK]J'_H8O#'_A/V_P#A1_Q"[./YH?\ @3_^1'_Q
M$'+.T_N7^9_1517\ZO\ Q$=?M0_]#%X8_P#"?M_\*_2+_@@A_P %#_B;^W]X
M;^)MS\2-0TV_E\+W.G16!L[".T"+,MR9-VS[W^J3KTQ7F9OP'F66X26,Q#AR
MQM>S=]6EV7<[\LXPP..Q,<+14N:5]TK:*_<_0BOG*/4+CQWJS:KHL"6/BS35
M9-0T]4"IJ48.'8*>">SH>O;FOHVOG*>6]\2:VT.I/_PCWCFP8&TNG_T==07H
M$<CY=_\ =;HPXKXM'U+*5N8)-,5[7_1]'O;H/97+<OH-[U\ICU\ML#GN,-U4
MBNW^#'C-?"FMSZ==$VUE?71A^SOP-+O.=T'IL?!*$?W<=<FN8:,ZREY=16NS
M5$RGB+02-GVI0>;B)?[P^]Q]T\C@\S6EB^J,L21VNK/<QA;4ROY:Z_:K_ [9
M^6YB^7!X;KUXRQ'T)17F'A#Q/K&G%;72I4UB&' ETO4Y/LVIV/\ L!CQ(OH3
M[<UVD?CRUB7_ $RVU'33W^TVK;%^LB[D_P#'JDHVZ*I:7XCT_7!FSOK2[QU\
MF97Q^1J[0 4444 >5?M-W/D#10=?FT-&\_(C$I-Q_JNR<<>Y[\=Z\CE30I_^
M/OQ7K5T.ZI8$Y_%Y1_*O8?VD;&^O&T4V6D66J;#/O-RN1#_J\8RP'.#US]VO
M.;?3O$T'W-*\'V>#C=(EAD'_ ($Q-4MB68*)X'B^_+XKN#_LQP19_-FK?\/G
MPM<X^P^!?$.LGC!>X<_^BQBKUM?>+K;IXC\&Z< >@FLDVG_@*&K<6I>(ICB\
M^)N@0+T_<70=A^2C^= %JPMGP/LOPC4>ANI<_P#H:5^#O_!>!9T_X*3^+A<Z
M1;Z%+_9^F9LH-NR(?8XL8V\<CG\:_=\R0;?])^+=T3W$"N,'VP]?@W_P72-N
M?^"D'BW[-JUQKD/V'3<7DY)>4_8XLYSSP>/PK](\+?\ D;R_Z]R_.)\+XA?\
MBV/^-?E(^0***53\W/3OBOZ"/Q<L:/;VUWJMO%>7+6=K)(%EG6+S3"IZMMR"
M<>@.:^A_VZ/V+-(_8[3P=+#XHM==NM?TN"Z-G'93JK2* )F9VV[5+?P?ZP9Y
M"\5T/Q?^%OP#T#]A?P]KF@S^(G^)$LXN[G2)M;LGN[*.Z4(KW&R#]Y;H;8,B
M*$D'VL%]H<5\N:OXFU'Q /\ 3[^]O<SR7)^T3M)F63'F2<D_,VU=QZG:,]*_
M(<DSC,>+,PH9MEE:MA,+A:E>E7HU*<$Z[5E"49>\U!/WE*+M.+]U]7]-B\+0
MRVA/#8B,:E2I&$H3C)^Y?5IK17Z6>S6O8^LOVH/CC\!?$?[&WAS0/!7@K0;#
MQ]:R1W-Z(+C4'@TMKJ,-<FWDE?\ ?NI@@C82[E3>?+W@,XRO"?[!GAKQ!_P3
MSU/XMOXRCAU&SO%N#;FQE,J6R'[/+"(P?G8W,L($H/E@=2"2!\J5H6OB>^@6
M&)KZ_P#LT4+6HB2Y9<0,Y=XEZ@*S,Q(QC+$D&N6CX5YAE.64LMX;S:O2MBOK
M%2567UB=2#ES5**E5OR1F]GK:\G)3;=])<14<3B)5\?AH2_=\D5%<B3M93M'
M=I?I:QGT5];?M>?#7X >%/V2?!%WX O=2O/'<7E)JUJVK6TTUFUU&;D_;-L0
M\YHMIA7R=@3^/#?*WR37VW W&='B?+I9C0P]6@E4G#EK1Y)/DE922N_=FK2B
M^L6FM+,\G-\KEE]=4)SC-M)WB[K5;7[K9^85^S__  :>?\B9\;O^OW1O_0+V
MOQ@K]G_^#3S_ )$SXW?]?NC?^@7M1XA_\B"O_P!N_P#I<3U^"?\ D<TO^WO_
M $EGZ\UX#X@NWAME\.?$6":-LEM.UJ/$C(,C@GJR^O?D9'0CWZO#-:37_A];
M&R\46 \7>%G;*7(R\ENO]X-]Y2!V)QV#5_-*/WAE#5K2YTBZTZSU>Y%KJ\6&
MT3Q)$V8KN/\ ACE/IR!DYQD9R.3=M-)@UO5-1C32)/M2X;6=!#!'CDXQ=6C9
MQGGIGD-CN*6&S;3]!/\ 9A_X2_P',09[5OFN],SG.T<,".H_'I]XJ%CM1;7C
MZI=7^A0+BPUVR&;W2O\ IE<*!EDZCY@?PSBF(Z/PU:2Z_H^T1V'C.RM7,8^V
M?N-3L2/^6;;@06&.I*GWK4\_^Q'\Y+[Q+HB(,M!?0&]ME'NXWX'TD%8^F07.
MKW'VR?3K/Q+!C":SHER+6\([>8H926]@W'I6[;ZW'IX_Y#FO6&/X-4L"8A_P
M-HP3_P!_*0R2"2'QQ&9(XO"7B94ZR*VQD_#$F#^(J.ZT)K9/W%OXGT5E.?,L
M[M;F$?2(L_'TC%1W+G7YQ) G@OQ+@\D,(91]#^]Y_$5=6V%FF7TWQ)IQ ^];
MW9N(U_W461O_ $"D,W_#!D_L.#SKFYO)/FS-<6_V>1_F/5-JXQTZ<@ ]Z*DT
M*3S=*B(ENY\Y^>ZB\J5N3U7:N/;Y1QCZT4 >3_M9'3@WA_\ M 7I'^D;!;E1
M_P \LYW ^WZUY-;S>%2__(/\13X':\B7]/*/\Z]K_:1O[ZR;1/L>MVNC;C/O
M,SLOF?ZO&,*W3)_,5YPOB371%A_B+81KG&$GN21^454MB7N9EH-!8?)X.U^Y
M[#=?GG_OF(5IVL&GL/W7POU68]<M=W3\?@@J2+7M08?/\3D7_=>[/_L@J6'4
M';_6?%:Z7_=%VW^% C9TE[P8^S?":T&>/])CSU]Y%K\(O^"\7VG_ (>4^+_M
M>DV^B3_8--W6<&W9%_H<6,;>.1S^-?N,+BQ60&;XLZKR<G9;W9_7=7X7?\%Q
MW@D_X*,>*S;ZO<:[%]@T[%[.KJ\O^B19R&^;CI^%?I'A=_R-Y?\ 7M_G$^&\
M0O\ D6Q_QK\I'R+74?!7P%9_%/XKZ!X:O=1NM*BUZ^BT]+JWLOMCQ22L$C_=
M;TW#<R@X;(&2 >AY>I+6XDM+A)(I&AD4Y5U8@J?7(YK]VS"C7K86I2PU3V=2
M46HSLGRR:TE9IIV>MFFGU/QRC*$:D95(\R35UW7;3N?0G_!2#]E7PA^R=\9+
M72?"/B.YUZPUBR34[=3;JT%O"2T6%N%D;S3YL4O 0;0 "6.:^=Z^@OB)^P=K
MG@+]D?0/BC=>)_"]QHNIW]S;P^3J?G1RILC,*P@+DS,Z70=, IY(+8YQ\^U\
M%X4YI2Q7#]/"QS)YC4PTI4:E=Q4)2J4Y.,E**5E)62>[ZMMN[]CB+#RIXUU'
M0]A&HE*,+W24E=6?9_\  0444^",33HK.L89@"[9VH/4X!./H*_2&[*YX9]+
M_LB_L:^#/V@?V>OB3XLU7Q?J6D:CX0T[S4M?[)23$B[KEV@_TA3<M]FMKA2F
M$V[PQR!7S3>+$EW(('DD@#$1O(@1V7/!*@D X[9/U-?1G[0O[ NO?LW?LT^!
M_B#=>)]"GM_$GF3I%::@7#LY4P&WPOS[H0'9N N #SC/S?7Y;X;9I'.*V89W
M@LU>-PE6LXTX<D8J@Z7[NI",E%2FG*/,F^_5MRE]#GN'>%C1PE7#^RJQC>3N
MVYJ7O1;5VEH[?U9%?L__ ,&GG_(F?&[_ *_=&_\ 0+VOQ@K]G_\ @T\_Y$SX
MW?\ 7[HW_H%[7O>(?_(@K_\ ;O\ Z7$Z>"?^1S2_[>_])9^O->1Z5X!\6?"M
M))_#%_:^(=)F^<V5P<$?[G.,]>A&>.#7KE>/6?PD-O,UW\/_ !<L.3F6W:X$
MT1/OM!_)E/UK^:4?O!E:*^B^*_%AN]%N;CP5XN4Y>RN%Q;3OW7&!U]./7:>M
M6IKR3P_XU\VZC'@OQ#<?*UR!YNDZI_O=-I/KGCOR:T=5U"^FLOLWCSP<VI*G
MR_VEI\8EVKZ_+\R?@1]*CT:.6^4Q^&M>T_Q5I3 ;]%U=LRHOHI8;ACMD8'O0
M(=KFCQPW"7NK>%KZ&X8?\A/PS.627OO*J0P^I!^M:F@>-K)@(;7QK/"R# BU
MJU0,/;)6-F_[Z-48;2QT-S_Q+_&/@^7.7%B&N;/=ZX4.F/\ @(J2+Q?J$?R+
MXW\-7JGCR]5LOLI/UPR\_A0,Z62RN_$*$O#X2\0+ZE3'_P#':SY?"']GOYL>
MBZW8,O)_LG5<QCZ1LZ@CVV?A4-K:_P!KJ#<:#X(U:3_GK:7:@Y]@T9(_[ZJX
M-'%N/^1=\16F.]EJH"+_ ,!$ZY_[YH ZCPQ,T^AP,WV_<=V?MJ!)_O'[P  ^
MG'3%%.\.KLT:$8O5^]Q=MNF^\?O')_#GIBBD,\Z_:5LWNWT39X<D\08\_A!/
M^X_U7_/(CK[^E>:VVC77\/PRE;;_ 'DOO_BZ]"_:E6Q;^POMNJ7VF_\ 'QL^
MSVWG>9_JLY^=,8X]>IZ5Y1!'H:_,/%VM1GI_R#3G])JI$O<Z"'2=1"\?#"/G
M^]%=?U:KD6FZNF"/A?I_MN@D/\VKGK=-"!!;QSK0[C&GR C_ ,BU<0: S?\
M)1-;7W-C-_\ %TP.ABT_74X'POT/G^]!G^;5^$/_  75CN8O^"D/BU;O2;71
M)Q8:;NL[=0L<?^AQ8P!QR.?QK]QHFT-N/^%GZT@ [V5S_P#%5^&7_!<3[/\
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:Y+9%Y_ 5>CA2'[JJN>N!C-%% #J*** /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
